PATH: Form 990, tax year 2014
View the entire original 990 at ProPublica ↗
- Organization
- PATH (EIN 91-1157127)
- Tax period
- 2014-01-01 to 2014-12-31
- Filed
- 2015-11-09
- IRS object ID
- 201543139349300449
- Schema version
- 2014v5.0
- Source
- Download XML · Original 990 at ProPublica
Every field in the e-filed return. Faint text is the IRS element name, for citing.
- Return header
- Form 990
- Schedule A
- Schedule B
- Schedule C
- Schedule D
- Schedule F
- Schedule G
- Schedule I
- Schedule J
- Schedule M
- Schedule O
- Schedule R
Return header ReturnHeader
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return | 2015-11-09T16:43:44-06:00 | ReturnTs |
| Tax Period End | 2014-12-31 | TaxPeriodEndDt |
Preparer Firm PreparerFirmGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Preparer Firm EIN | 521392008 | PreparerFirmEIN |
Preparer Firm Name PreparerFirmName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | GELMAN ROSENBERG & FREEDMAN | BusinessNameLine1Txt |
Preparer US Address PreparerUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 4550 MONTGOMERY AVE SUITE 650N | AddressLine1Txt |
| City | BETHESDA | CityNm |
| State Abbreviation | MD | StateAbbreviationCd |
| ZIP | 208142930 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Return Type | 990 | ReturnTypeCd |
| Tax Period Begin | 2014-01-01 | TaxPeriodBeginDt |
Filer Filer
| Field | Value | IRS element (for citing) |
|---|---|---|
| EIN | 911157127 | EIN |
Business Name BusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | PATH | BusinessNameLine1Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Control | PATH | BusinessNameControlTxt |
| Phone | 2062853500 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 2201 WESTLAKE AVENUE NO 200 | AddressLine1Txt |
| City | SEATTLE | CityNm |
| State Abbreviation | WA | StateAbbreviationCd |
| ZIP | 98121 | ZIPCd |
Business Officer BusinessOfficerGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Person | STEVE DAVIS | PersonNm |
| Person Title | CHIEF FINANCIAL OFFICER | PersonTitleTxt |
| Phone | 2062853500 | PhoneNum |
| Signature | 2015-11-09 | SignatureDt |
| Discuss With Paid Preparer | Yes (1) | DiscussWithPaidPreparerInd |
Preparer Person PreparerPersonGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Phone | 3019519090 | PhoneNum |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Tax | 2014 | TaxYr |
| Build TS | 2016-04-25 22:37:26Z | BuildTS |
Form 990 IRS990
| Field | Value | IRS element (for citing) |
|---|---|---|
| Principal Officer | STEVE DAVIS | PrincipalOfficerNm |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 2201 WESTLAKE AVENUE NO 200 | AddressLine1Txt |
| City | SEATTLE | CityNm |
| State Abbreviation | WA | StateAbbreviationCd |
| ZIP | 98121 | ZIPCd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Gross Receipts | $346,979,287 | GrossReceiptsAmt |
| Group Return For Affiliates | 0 | GroupReturnForAffiliatesInd |
| Organization501c3 | Yes (X) | Organization501c3Ind |
| Website Address | WWW.PATH.ORG | WebsiteAddressTxt |
| Type Of Organization Corp | Yes (X) | TypeOfOrganizationCorpInd |
| Formation | 1981 | FormationYr |
| Legal Domicile State | WA | LegalDomicileStateCd |
| Activity Or Mission | SEE PART III, LINE 1. | ActivityOrMissionDesc |
| Voting Members Governing Body | 15 | VotingMembersGoverningBodyCnt |
| Voting Members Independent | 15 | VotingMembersIndependentCnt |
| Total Employee | 746 | TotalEmployeeCnt |
| Total Volunteers | 0 | TotalVolunteersCnt |
| Total Gross UBI | $0 | TotalGrossUBIAmt |
| Net Unrelated Bus Txbl Incm | $0 | NetUnrelatedBusTxblIncmAmt |
| PY Contributions Grants | $260,656,932 | PYContributionsGrantsAmt |
| CY Contributions Grants | $286,891,535 | CYContributionsGrantsAmt |
| PY Program Service Revenue | $3,946 | PYProgramServiceRevenueAmt |
| CY Program Service Revenue | $22,378 | CYProgramServiceRevenueAmt |
| PY Investment Income | $2,050,396 | PYInvestmentIncomeAmt |
| CY Investment Income | $1,565,398 | CYInvestmentIncomeAmt |
| PY Other Revenue | $2,433,300 | PYOtherRevenueAmt |
| CY Other Revenue | $801,633 | CYOtherRevenueAmt |
| PY Total Revenue | $265,144,574 | PYTotalRevenueAmt |
| CY Total Revenue | $289,280,944 | CYTotalRevenueAmt |
| PY Grants And Similar Paid | $72,704,584 | PYGrantsAndSimilarPaidAmt |
| CY Grants And Similar Paid | $71,872,357 | CYGrantsAndSimilarPaidAmt |
| PY Benefits Paid To Members | $0 | PYBenefitsPaidToMembersAmt |
| CY Benefits Paid To Members | $0 | CYBenefitsPaidToMembersAmt |
| PY Salaries Comp Emp Bnft Paid | $101,626,168 | PYSalariesCompEmpBnftPaidAmt |
| CY Salaries Comp Emp Bnft Paid | $110,831,078 | CYSalariesCompEmpBnftPaidAmt |
| PY Total Prof Fndrsng Expns | $0 | PYTotalProfFndrsngExpnsAmt |
| CY Total Prof Fndrsng Expns | $0 | CYTotalProfFndrsngExpnsAmt |
| CY Total Fundraising Expense | $3,257,077 | CYTotalFundraisingExpenseAmt |
| PY Other Expenses | $111,371,191 | PYOtherExpensesAmt |
| CY Other Expenses | $93,920,413 | CYOtherExpensesAmt |
| PY Total Expenses | $285,701,943 | PYTotalExpensesAmt |
| CY Total Expenses | $276,623,848 | CYTotalExpensesAmt |
| PY Revenues Less Expenses | -$20,557,369 | PYRevenuesLessExpensesAmt |
| CY Revenues Less Expenses | $12,657,096 | CYRevenuesLessExpensesAmt |
| Total Assets BOY | $485,822,280 | TotalAssetsBOYAmt |
| Total Assets EOY | $495,616,246 | TotalAssetsEOYAmt |
| Total Liabilities BOY | $57,067,664 | TotalLiabilitiesBOYAmt |
| Total Liabilities EOY | $54,206,418 | TotalLiabilitiesEOYAmt |
| Net Assets Or Fund Balances BOY | $428,754,616 | NetAssetsOrFundBalancesBOYAmt |
| Net Assets Or Fund Balances EOY | $441,409,828 | NetAssetsOrFundBalancesEOYAmt |
| Info In Schedule O Part III | Yes (X) | InfoInScheduleOPartIIIInd |
| Mission | OUR MISSION IS TO IMPROVE THE HEALTH OF PEOPLE AROUND THE WORLD BY ADVANCING TECHNOLOGIES, STRENGTHENING SYSTEMS, AND ENCOURAGING HEALTHY BEHAVIORS. (CONTINUED ON SCHEDULE O) | MissionDesc |
| Significant New Program Srvc | 0 | SignificantNewProgramSrvcInd |
| Significant Change | 0 | SignificantChangeInd |
| Expense | $108,848,538 | ExpenseAmt |
| Grant | $39,768,359 | GrantAmt |
| Revenue | $750 | RevenueAmt |
| Desc | PRODUCT DEVELOPMENT: PATH IS A GLOBAL LEADER IN IDENTIFYING, DEVELOPING, AND INTRODUCING AFFORDABLE, EFFECTIVE, AND EASY-TO-USE HEALTH TECHNOLOGIES TO ADDRESS URGENT HEALTH CHALLENGES. OUR VACCINES, DRUGS, DIAGNOSTICS, DEVICES AND TOOLS, AND DIGITAL HEALTH SOLUTIONS ARE EMPOWERING COMMUNITIES AND TRANSFORMING HEALTH WORLDWIDE, PARTICULARLY IN LOW-RESOURCE SETTINGS.PATH SPECIALIZES IN USHERING HEALTH TECHNOLOGIES AND SYSTEMS INNOVATIONS ALL THE WAY FROM BRIGHT IDEA TO LIFESAVING USE IN COMMUNITIES AROUND THE WORLD. WE OVERCOME BARRIERS ON THIS "JOURNEY OF INNOVATION," INCLUDING MARKET CONCERNS, GAPS IN DEMAND AND SUPPLY, POLICY AND REGULATORY ROADBLOCKS, INTRODUCTION, AND OTHER CONSIDERATIONS TO ENSURE THAT SMART SOLUTIONS REACH THE PEOPLE WHO NEED THEM. KEY TO THIS EFFORT IS OUR WORK TO ACCELERATE THE DEVELOPMENT AND DELIVERY OF SAFE, EFFECTIVE, AND LOW-COST VACCINES AGAINST DISEASES THAT THREATEN WOMEN AND CHILDREN WORLDWIDE, INCLUDING THOSE THAT ARE NOT WELL-RECOGNIZED IN WEALTHY COUNTRIES. OUR PORTFOLIO INCLUDES VACCINES FOR DIARRHEAL DISEASE, INFLUENZA, JAPANESE ENCEPHALITIS, MALARIA, MENINGITIS, PNEUMOCOCCAL DISEASE, POLIO, AND MORE. WE ALSO ADVANCE INNOVATIVE DELIVERY STRATEGIES TO HELP VACCINES REACH THE PEOPLE WHOSE LIVES THEY CAN PROTECT. IN 2014, OUR EFFORTS BROUGHT VACCINES TO MORE COMMUNITIES (SOME FOR THE FIRST TIME); ADVANCED PROMISING NEW VACCINE CANDIDATES; AND STRENGTHENED THE SUPPLY CHAINS AND SYSTEMS NECESSARY FOR SAFE VACCINE DELIVERY, STORAGE, AND ADMINISTRATION. FOR EXAMPLE, WE COLLABORATED WITH COUNTRY LEADERS AND PARTNERS IN CAMBODIA, INDIA, AND LAOS TO BRING A SAFE AND EFFECTIVE VACCINE AGAINST JAPANESE ENCEPHALITIS TO AN ESTIMATED 14 MILLION MORE CHILDREN. WE ALSO LAID THE GROUNDWORK FOR ITS INTRODUCTION IN ADDITIONAL REGIONS AND COUNTRIES. JAPANESE ENCEPHALITIS, OFTEN CALLED "BRAIN FEVER," IS AN INCURABLE DISEASE COMMON IN SOUTHEAST ASIA AND THE WESTERN PACIFIC. VACCINE INTRODUCTIONS ARE A CRUCIAL STEP IN A PATH-LED PROCESS THAT HAS INCLUDED IDENTIFYING THE LITTLE-KNOWN VACCINE IN CHINA, PROVING THAT IT IS SAFE AND EFFECTIVE, HELPING THE CHINESE MANUFACTURER ENSURE A GLOBAL SUPPLY, AND SECURING AN AFFORDABLE PUBLIC-SECTOR PRICE. WE ALSO USHERED THE VACCINE THROUGH WORLD HEALTH ORGANIZATION PREQUALIFICATION, WHICH MAKES IT EASIER FOR COUNTRIES TO OBTAIN FUNDING TO PURCHASE AND ROLL OUT THE VACCINE. IN 2014, WE ALSO REACHED 64 MILLION AFRICANS WITH THE MENAFRIVAC VACCINE, DEVELOPED BY PATH, WHO, AND THE SERUM INSTITUTE OF INDIA LTD. TO PROTECT CHILDREN AND YOUNG PEOPLE FROM DEADLY AND DEBILITATING MENINGITIS A. SINCE THE VACCINE'S INTRODUCTION IN 2010, MORE THAN 217 MILLION PEOPLE HAVE BEEN IMMUNIZED. IN 2014, WE CELEBRATED A CAPSTONE ACHIEVEMENT FOR THIS 14-YEAR EFFORT: THE WORLD HEALTH ORGANIZATION DETERMINED THAT, STARTING IN 2015, THE VACCINE CAN SAFELY BE INCLUDED IN ROUTINE IMMUNIZATIONS FOR INFANTS. THIS WILL HELP ENSURE BROAD PROTECTION INTO THE FUTURE. [MENAFRIVAC IS A REGISTERED TRADEMARK OF SERUM INSTITUTE OF INDIA LTD.]WE'RE ALSO ACCELERATING THE DEVELOPMENT OF MORE THAN 20 MALARIA VACCINE CANDIDATES AND APPROACHES. THIS YEAR, THE PIVOTAL PHASE 3 TRIAL OF ONE OF THESE-THE RTS, S MALARIA VACCINE CANDIDATE-CONCLUDED, AND OUR DEVELOPMENT PARTNER, GLAXOSMITHKLINE, SUBMITTED THE FILE FOR REGULATORY REVIEW. THIS WORK PAVED THE WAY FOR A POSITIVE SCIENTIFIC OPINION FROM EUROPEAN REGULATORS IN 2015, AND OPENED THE DOOR FOR A RECOMMENDATION BY THE WORLD HEALTH ORGANIZATION, ANTICIPATED IN LATE 2015. BOTH WILL SUPPORT WIDER ADOPTION AND INTRODUCTION OF THE VACCINE. AN AFFORDABLE NEW VACCINE AGAINST THE MOST LETHAL FORM OF DIARRHEA, ROTAVAC, WAS ALSO A FOCUS. THE VACCINE REDUCES SEVERE ROTAVIRUS DIARRHEA BY 56 PERCENT IN THE FIRST YEAR OF LIFE AT A FRACTION OF THE PRICE OF CURRENTLY AVAILABLE VACCINES. IN EARLY 2014, ROTAVAC OBTAINED LICENSURE IN INDIA, AND IN JULY 2014, THE PRIME MINISTER ANNOUNCED THAT IT WILL BE INCLUDED IN THE NATIONAL IMMUNIZATION PROGRAM. [ROTAVAC IS A REGISTERED TRADEMARK OF BHARAT BIOTECH INTERNATIONAL LTD.]FINALLY, THE BETTER IMMUNIZATION DATA INITIATIVE, A COLLABORATION BETWEEN PATH AND SUB-SAHARAN AFRICAN COUNTRIES, CONTINUED TO EMPOWER NATIONAL HEALTH SYSTEMS TO ENHANCE IMMUNIZATION THROUGH IMPROVED DATA COLLECTION, QUALITY, AND USE. THE INITIATIVE PARTNERED WITH MORE THAN 12 COUNTRIES TO DESIGN EFFECTIVE, SCALABLE INTERVENTIONS AND WORKED DIRECTLY WITH TWO DEMONSTRATION COUNTRIES, TANZANIA AND ZAMBIA, TO IMPROVE ROUTINE IMMUNIZATION SERVICE DELIVERY. IN 2014, FOR INSTANCE, WE LAID THE GROUNDWORK FOR THE 2015 LAUNCH OF A NEW NATIONAL ELECTRONIC IMMUNIZATION REGISTRY IN TANZANIA. THE REGISTRY WILL HELP HEALTH WORKERS TRACK CHILDREN'S IMMUNIZATIONS, FLAG THOSE WHO HAVE MISSED A POTENTIALLY LIFESAVING VACCINE, AND ALERT CAREGIVERS.PATH'S IMPORTANT DRUG DEVELOPMENT WORK CONTINUED IN 2014. OUR EFFORTS FOCUS ON DEVELOPING AND ENSURING THE AVAILABILITY AND ACCESSIBILITY OF SAFE AND EFFECTIVE DRUGS FOR DISEASES THAT DISPROPORTIONATELY AFFECT PEOPLE IN LOW-INCOME COUNTRIES. THESE INCLUDE DIARRHEA, PARASITIC DISEASES, HIV, MALARIA, AND INFECTIONS THAT THREATEN YOUNG CHILDREN AND NEWBORNS. THIS YEAR, 1.7 MILLION MALARIA TREATMENTS MADE WITH A NOVEL INGREDIENT CALLED SEMISYNTHETIC ARTEMISININ WERE DELIVERED TO BURUNDI, LIBERIA, NIGER, AND OTHER COUNTRIES. THE ROLLOUT OF THESE MALARIA TREATMENTS WAS A KEY MILESTONE FOR A GLOBAL PARTNERSHIP CONVENED BY PATH TO CREATE A STABLE, HIGH-QUALITY SOURCE OF ARTEMISININ. SEMISYNTHETIC ARTEMISININ WILL COMPLEMENT THE BOTANICAL SUPPLY AND HAS HELPED TO STRENGTHEN THE SUPPLY CHAIN, STABILIZE PRICING, AND ENSURE AVAILABILITY. IN ADDITION, WE CONTINUED WORK TO TEST NEW, AND OPTIMIZE EXISTING, TREATMENTS THAT LESSEN THE BURDEN OF ENTERIC (INTESTINAL) DISEASES IN CHILDREN. THIS INCLUDES RESEARCH AND DEVELOPMENT OF SAFE AND EFFECTIVE NEW THERAPEUTICS FOR CRYPTOSPORIDIUM INFECTION, A LEADING CAUSE OF DEADLY DIARRHEAL DISEASE AMONG YOUNG CHILDREN THAT CAN CONTRIBUTE TO CHRONIC MALNUTRITION, STUNTED GROWTH, AND DELAYED MENTAL DEVELOPMENT. WITH GLOBAL PARTNERS, WE ADVANCED THE DEVELOPMENT OF A LONG-ACTING INJECTABLE FORMULATION OF PRE-EXPOSURE PROPHYLAXIS (PREP) TO PREVENT HIV INFECTION. SUCH FORMULATIONS HAVE THE POTENTIAL TO IMPROVE UPTAKE AND ADHERENCE OF HIV PREP AND COULD EXPAND THE GLOBAL TOOLBOX OF PREVENTION INTERVENTIONS, PROVIDING SAFE AND EFFECTIVE CHOICES TO ADDRESS DIFFERENT CIRCUMSTANCES AND PREFERENCES.PATH ALSO CONTINUED AN INTERNATIONAL EFFORT TO EXPAND THE USE OF A PROVEN ANTISEPTIC, CHLORHEXIDINE, INTO A NEW FORMULATION FOR USE ON BABIES' NEWLY CUT UMBILICAL CORDS. BETWEEN 2015 AND 2030, AN ESTIMATED 1,004,000 NEONATAL LIVES COULD BE SAVED EACH YEAR WITH GREATER USE OF CHLORHEXIDINE, AT A COST OF LESS THAN 50 CENTS A DOSE. PATH IS HELPING TO SUPPORT MORE THAN 20 COUNTRIES TO ADOPT THE DRUG AND INCREASE LOCAL PRODUCTION.FOR PATH'S BROAD DEVICES AND TOOLS PORTFOLIO, WE WORK WITH THE PEOPLE WE SERVE TO DEVELOP, ADAPT, AND INTRODUCE SOLUTIONS THAT IMPROVE MATERNAL, NEWBORN, AND REPRODUCTIVE HEALTH; NUTRITION; VACCINE DELIVERY; WATER AND SANITATION; AND MORE.THIS YEAR, WE CONTINUED TO DEVELOP AND INTRODUCE EFFECTIVE, USER-CONTROLLED CONTRACEPTIVE OPTIONS FOR THE 222 MILLION WOMEN WORLDWIDE WHO WANT TO AVOID PREGNANCY BUT ARE NOT USING MODERN CONTRACEPTION. THE CAYA CONTOURED DIAPHRAGM, DEVELOPED BY PATH AND OUR PARTNERS AS THE SILCS DIAPHRAGM, RECEIVED REGULATORY APPROVAL IN CANADA. IN ADDITION, MARKET CLEARANCE BY THE US FOOD AND DRUG ADMINISTRATION OPENED THE DOOR FOR SUBSEQUENT INTRODUCTION IN THE UNITED STATES IN 2015, PAVING THE WAY FOR INTRODUCTION IN MORE DEVELOPING-COUNTRY MARKETS. THE CAYA DIAPHRAGM'S DESIGN AND SPECIFICATIONS WERE INFORMED BY INPUT FROM WOMEN AND HEALTH CARE PROVIDERS. AS OF 2014, THE PRODUCT IS IN MORE THAN 15 COUNTRIES, INCLUDING EUROPEAN NATIONS. [CAYA IS A REGISTERED TRADEMARK OF KESSEL MEDINTIM GMBH.]PATH AND OUR PARTNERS ALSO ADVANCED WATER FILTERS AND TREATMENT DEVICES, INCLUDING THE GROUNDBREAKING MOUNTAIN SAFETY RESEARCH SE200 COMMUNITY CHLORINE MAKER, AVAILABLE IN 2015, WHICH CAN CREATE ENOUGH CHLORINE TO TREAT 55 GALLONS OF WATER AT THE TOUCH OF A BUTTON. [SE200 IS A REGISTERED TRADEMARK OF CASCADE DESIGNS, INC.]PATH ALSO WORKS TO DEVELOP AND INTRODUCE FAST, ACCURATE DIAGNOSTIC TECHNOLOGIES, INCLUDING TOOLS TO DETECT AND MONITOR CERVICAL CANCER, DIABETES, HIV, MALARIA, NEGLECTED TROPICAL DISEASES, TUBERCULOSIS (TB), AND OTHER DISEASES. | Desc |
Prog Srvc Accom Acty2 ProgSrvcAccomActy2Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $71,547,298 | ExpenseAmt |
| Grant | $16,148,119 | GrantAmt |
| Revenue | $1,083 | RevenueAmt |
| Desc | PUBLIC HEALTH: PATH'S PUBLIC HEALTH PORTFOLIO FOCUSES ON SEVERAL KEY AREAS: REPRODUCTIVE HEALTH; MATERNAL, NEWBORN, AND CHILD HEALTH AND NUTRITION; NONCOMMUNICABLE DISEASES; MALARIA CONTROL AND ELIMINATION; AND HIV/AIDS AND TB PROGRAMS. IT ALSO SUPPORTS CROSS-PROGRAM COLLABORATIONS THAT INCREASE OUR IMPACT BY PUTTING OUR RESOURCES TO BEST USE. THROUGHOUT THESE EFFORTS, WE COLLABORATE WITH GOVERNMENTS, COMMUNITIES, AND CIVIL SOCIETY GROUPS AROUND THE WORLD TO STRENGTHEN THE LOCAL AND NATIONAL HEALTH SYSTEMS THAT PROVIDE CRUCIAL SERVICES. WE ALSO DEVELOP AND INTRODUCE PROVEN STRATEGIES TO IMPROVE HEALTH AND ENCOURAGE HEALTHY BEHAVIORS. IN 2014, WE CONTINUED OUR EFFORTS TO REDUCE THE BURDEN OF HIV/AIDS AND TB WORLDWIDE. WITH PARTNERS, WE WORKED TO DEVELOP APPROPRIATE, AFFORDABLE, AND EVIDENCE-BASED SCREENING TOOLS, DIAGNOSTICS, AND DRUGS; STRENGTHEN HEALTH SYSTEMS; AND INTEGRATE SERVICES FOR HIV AND RELATED CONDITIONS SUCH AS TB AND DIABETES. WE ALSO MOBILIZED LOCAL COMMUNITIES, PUBLIC AND PRIVATE PARTNERS, GOVERNMENTS, AND LEADERS TO INCREASE HEALTHY BEHAVIORS AND CONFRONT STIGMA AND GENDER-BASED VIOLENCE.FOR EXAMPLE, UNDER PROVIC, AN HIV/AIDS PROJECT IN THE DEMOCRATIC REPUBLIC OF THE CONGO, WE COUNSELED MORE THAN 166,390 PEOPLE ON HIV PREVENTION AND RISK REDUCTION AND MADE MORE THAN 131,730 PEOPLE AWARE OF THEIR HIV STATUS AND LINKED THEM TO SERVICES. WE SCREENED NEARLY 80,000 PREGNANT WOMEN FOR HIV AND HELPED 93 PERCENT OF THOSE WHO WERE POSITIVE BEGIN TREATMENT TO REDUCE THE RISK OF TRANSMISSION TO THEIR CHILDREN. AND WE REACHED THOUSANDS OF MEN AND WOMEN WITH SERVICES FOR TB, FAMILY PLANNING, AND NUTRITION AND PROVIDED COUNSELING AND SCREENING FOR GENDER BASED VIOLENCE. PATH'S COMPREHENSIVE STRATEGY TO ELIMINATE MALARIA IN AFRICA INCLUDES WORKING WITH NATIONAL MALARIA PROGRAMS IN A NUMBER OF COUNTRIES TO INCREASE THE USE OF PROVEN INTERVENTIONS, SUCH AS INSECTICIDE-TREATED BED NETS; STRENGTHEN QUICK AND EFFECTIVE CASE MANAGEMENT; GIVE MORE PEOPLE ACCESS TO DIAGNOSIS AND TREATMENT; FIND NEW WAYS TO REMOVE THE MALARIA PARASITE FROM POPULATIONS COMPLETELY; AND BUILD STRONG REPORTING SYSTEMS. IN 2014, WE PARTNERED WITH THE ZAMBIAN MINISTRY OF HEALTH TO RESEARCH NEW WAYS TO MONITOR AND ELIMINATE MALARIA IN AREAS WHERE PRIOR EFFORTS HAVE ALREADY LOWERED RATES. FOR INSTANCE, WE ARE EXPLORING THE EFFICACY OF TREATING ENTIRE COMMUNITIES WITH SAFE AND EFFECTIVE ANTIMALARIA DRUGS. IN SENEGAL, PATH AND OUR PARTNERS ARE SUPPORTING HEALTH CARE WORKERS TO CREATE "MALARIA-FREE ZONES" BY INVESTIGATING, IDENTIFYING, AND TREATING POCKETS OF SUSPECTED CASES BEFORE THEY GROW. IN AREAS WITH MORE INFECTIONS, WORKERS ALSO SCREEN ALL PEOPLE WITH FEVERS, TEST ENTIRE COMMUNITIES, AND PROVIDE TREATMENT. IN 2014, WE EXPANDED OUR EFFORTS TO FOUR NEW REGIONS, AND WE ARE MONITORING RESULTS.OUR REPRODUCTIVE HEALTH PROGRAM CONTINUED ITS WORK TO STRENGTHEN ACCESS TO FAMILY PLANNING, IMPROVE SCREENING AND TREATMENT FOR CERVICAL AND BREAST CANCERS, PREVENT SEXUALLY TRANSMITTED INFECTIONS, ADVOCATE FOR HEALTH SERVICES AND SUPPLIES, INTRODUCE CONTRACEPTIVE TECHNOLOGIES, AND ENCOURAGE HEALTHY BEHAVIORS. A KEY FOCUS IS ENSURING THAT WOMEN HAVE ACCESS TO A VARIETY OF SAFE AND AFFORDABLE CONTRACEPTIVE OPTIONS. IN AN IMPORTANT MILESTONE, PILOT INTRODUCTIONS OF A GROUNDBREAKING NEW FORM OF INJECTABLE CONTRACEPTION, SAYANA PRESS, REACHED THOUSANDS OF WOMEN FOR THE FIRST TIME IN 2014. SAYANA PRESS COMBINES A LOWER-DOSE FORMULATION OF THE WIDELY USED INJECTABLE CONTRACEPTIVE DEPO-PROVERA WITH THE PATH-DEVELOPED UNIJECT INJECTION SYSTEM. FOR THE PILOT PROJECTS, PATH AND OUR PARTNERS TRAINED 3,000 HEALTH WORKERS IN FOUR COUNTRIES TO DELIVER THE CONTRACEPTIVE. BY THE END OF 2014, SAYANA PRESS WAS BEING USED BY THOUSANDS OF WOMEN ACROSS BURKINA FASO, NIGER, AND UGANDA; SENEGAL WAS ON THE VERGE OF INTRODUCTION. IN ADDITION, KEY HEALTH PARTNERS ANNOUNCED A SIGNIFICANT PRICE REDUCTION FOR SAYANA PRESS THAT WILL GIVE MILLIONS MORE WOMEN ACCESS TO THE CONTRACEPTIVE AT REDUCED OR NO COST.[SAYANA AND DEPO-PROVERA ARE REGISTERED TRADEMARKS OF PFIZER INC. AND/OR ITS AFFILIATES. UNIJECT IS A TRADEMARK OF BD.]OUR WORK INCLUDED SEVERAL PROJECTS TO PREVENT, DETECT, AND TREAT HUMAN PAPILLOMAVIRUS (HPV), THE PRIMARY CAUSE OF CERVICAL CANCER WORLDWIDE. IN UGANDA, WE SUPPORTED THE MINISTRY OF HEALTH TO IMPLEMENT A TOOLKIT OF APPROACHES, INCLUDING VACCINATION FOR YOUNG WOMEN, EFFECTIVE AND AFFORDABLE SCREENING TOOLS, AND NATIONAL POLICIES TO PRIORITIZE HPV. WE ARE ALSO PARTNERING TO ASSESS NEW TECHNOLOGIES THAT CAN IMPROVE DETECTION AND TREATMENT. IN GUATEMALA, PATH SUPPORTED THE MINISTRY OF PUBLIC HEALTH AND SOCIAL ASSISTANCE TO RELEASE NEW NATIONAL GUIDELINES FOR THE SCREENING AND PREVENTION OF CERVICAL CANCER. THE GUIDELINES CAN SAVE WOMEN'S LIVES BY GIVING HEALTH CARE WORKERS LEADING-EDGE APPROACHES TO STOP CANCER BEFORE IT STARTS.WE ALSO CONTINUE TO SERVE AS THE SECRETARIAT FOR THE REPRODUCTIVE HEALTH SUPPLIES COALITION, A GLOBAL PARTNERSHIP OF 300 PUBLIC, PRIVATE, AND NONGOVERNMENTAL ORGANIZATIONS WORKING TO EXPAND ACCESS TO SUPPLIES, SERVICES, AND OPTIONS FOR PREVENTING UNINTENDED PREGNANCIES AND SEXUALLY TRANSMITTED INFECTIONS. 2014 BROUGHT TREMENDOUS GROWTH IN OUR NONCOMMUNICABLE DISEASES (NCD) PROGRAM. WE ARE APPLYING OUR IN-COUNTRY EXPERTISE AND OUR KNOWLEDGE OF PRODUCT AND MARKET DEVELOPMENT, DIAGNOSTICS, AND HEALTH SYSTEMS STRENGTHENING TO ADDRESS THE GROWING HEALTH AND ECONOMIC CHALLENGES ASSOCIATED WITH RISING NCD PREVALENCE. OUR GOAL IS TO REDUCE PREVENTABLE ILLNESS AND DEATH BY INCREASING ACCESS TO PREVENTION AND CARE FOR THESE DISEASES. THIS YEAR, BUILDING ON OUR SUCCESSFUL WORK TO REDUCE THE BURDEN OF BREAST AND CERVICAL CANCERS IN LOW-RESOURCE COUNTRIES, WE INCREASED OUR EFFORTS IN DIABETES AND EXPANDED OUR PORTFOLIO TO INCLUDE HYPERTENSION. WE CURRENTLY HAVE MORE THAN A DOZEN ACTIVE NCD PROJECTS IN VARIOUS STAGES, FROM RESEARCH AND DEVELOPMENT TO IMPLEMENTATION. MANY OF THESE EFFORTS ARE IMPLEMENTED IN PARTNERSHIP WITH MINISTRIES OF HEALTH TO ADDRESS CHALLENGES IN PROVIDING NCD PREVENTION AND CARE. FOR EXAMPLE, THE NO EMPTY SHELVES PROJECT IS GATHERING EVIDENCE AND MOBILIZING STAKEHOLDERS TO IMPROVE THE AVAILABILITY AND AFFORDABILITY OF ESSENTIAL NCD MEDICINES AND TECHNOLOGIES IN LOW-RESOURCE SETTINGS WORLDWIDE, WITH AN INITIAL FOCUS ON DIABETES. PATH'S MATERNAL, NEWBORN, AND CHILD HEALTH AND NUTRITION PROGRAM CONTINUED TO WORK WITH PARTNERS TO DESIGN AND IMPLEMENT EVIDENCE-BASED TECHNOLOGIES AND APPROACHES THAT REDUCE MATERNAL AND CHILD ILLNESS AND DEATH AND GIVE CHILDREN THE BEST POSSIBLE START IN LIFE. OUR INTEGRATED AND COST-EFFECTIVE SOLUTIONS ARE REACHING MOTHERS AND CHILDREN IN 19 COUNTRIES ACROSS AFRICA, ASIA, EASTERN EUROPE, THE MIDDLE EAST, AND LATIN AMERICA AND THE CARIBBEAN. IN 2014, WE CONTINUED TO PLAY A CATALYTIC ROLE IN ENSURING THAT FORTIFIED RICE PRODUCED THROUGH OUR ULTRA RICE FORTIFICATION TECHNOLOGY REACHES CHILDREN AND FAMILIES WORLDWIDE. WE CONTINUED TO BOLSTER LOCAL PRODUCTION, ESTABLISH QUALITY ASSURANCE SYSTEMS, AND SUPPORT MARKETING. THIS YEAR, OUR EFFORTS ACHIEVED A MILESTONE IN BRAZIL: A STUNNING 2 MILLION PEOPLE REACHED SINCE INTRODUCTION. AND IN MYANMAR, WE'RE WORKING TO BUILD RICE-FORTIFICATION CAPACITY AND INCREASE CONSUMER DEMAND. [ULTRA RICE IS A REGISTERED TRADEMARK OF BON DENTE INTERNATIONAL, INC.]PATH IS A LEADER IN STRENGTHENING HUMAN MILK BANKING (HMB) TO ENSURE THAT VULNERABLE INFANTS HAVE ACCESS TO LIFESAVING DONATED BREAST MILK WHEN THEIR MOTHERS' OWN MILK ISN'T AVAILABLE. IN 2014, WE ADVANCED AN INNOVATIVE MODEL IN WHICH BANKS ARE NOT JUST DONATION SITES, BUT HUBS OF CARE THAT PROVIDE BREASTFEEDING SUPPORT, PROMOTE CRUCIAL SKIN-TO-SKIN CONTACT, AND ENGAGE COMMUNITIES. WE REFINED A LOW-COST SYSTEM, FONEASTRA, THAT USES MOBILE PHONES TO HELP HEALTH WORKERS PASTEURIZE MILK. IN SOUTH AFRICA, WE HELPED THE NATIONAL HMB ASSOCIATION SAFELY AND SUSTAINABLY EXPAND BANKING. AND WE RECEIVED FUNDING TO HELP THE GOVERNMENT OF INDIA DEVELOP NATIONAL HMB GUIDANCE AND TO ESTABLISH A LEARNING EXCHANGE THAT LINKS INDIAN STAKEHOLDERS WITH EXPERTS IN BRAZIL'S GLOBALLY RECOGNIZED HMB SYSTEM. | Desc |
Prog Srvc Accom Acty3 ProgSrvcAccomActy3Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $36,892,844 | ExpenseAmt |
| Grant | $12,416,472 | GrantAmt |
| Desc | INTERNATIONAL DEVELOPMENTPATH'S ON-THE-GROUND EXPERIENCE ALLOWS US TO APPLY TAILOR-MADE SOLUTIONS TO URGENT HEALTH NEEDS IN THE COMMUNITIES WE SERVE. WE COLLABORATE WITH COUNTRY PARTNERS TO IMPLEMENT SUSTAINABLE, COUNTRY-OWNED INNOVATIONS THAT STRENGTHEN HEALTH SYSTEMS, ENCOURAGE HEALTHIER BEHAVIORS, AND FOSTER MORE EQUAL ACCESS TO CARE AND SERVICES. IN 2014, OUR INTERNATIONAL DEVELOPMENT PORTFOLIO SUPPORTED OFFICES IN 19 COUNTRIES. THIS WORK RANGED FROM SMALL-SCALE PILOTS TO LARGE, MULTI-COUNTRY EFFORTS. THROUGHOUT, OUR SOLUTIONS WERE DESIGNED TO COMPLEMENT EXISTING COUNTRY AND COMMUNITY STRENGTHS, PRIORITIES, AND PROGRAMS. EXAMPLES INCLUDE:OUR MEKONG REGIONAL PROGRAM, BASED IN HANOI, VIETNAM, WORKS TO IMPROVE HEALTH SYSTEMS AND TACKLE PERSISTENT HEALTH THREATS IN VIETNAM, MYANMAR, CAMBODIA, AND LAOS. WE WORK WITH GOVERNMENTS TO IMPROVE VACCINE DELIVERY SYSTEMS; INTRODUCE NEW VACCINES; ADDRESS INFECTIOUS DISEASES INCLUDING HIV, TB, AND MALARIA; IMPROVE SCREENING AND TREATMENT FOR NCDS SUCH AS HYPERTENSION; AND IMPROVE REPRODUCTIVE AND MATERNAL AND CHILD HEALTH. AMONG OTHER HIGHLIGHTS IN 2014, WE SUPPORTED NATIONAL LEADERS TO INTRODUCE THE JAPANESE ENCEPHALITIS VACCINE IN KEY DISTRICTS OF CAMBODIA AND LAOS. THIS AFFORDABLE, EFFECTIVE VACCINE, ADVANCED THROUGH THE WORK OF PATH AND OUR PARTNERS, REACHED AN ESTIMATED 14 MILLION CHILDREN IN THESE TWO COUNTRIES AND THROUGH SIMILAR EFFORTS IN INDIA.OUR HEALTHY MARKETS PROJECT IS HELPING THE GOVERNMENT OF VIETNAM BUILD A COMMERCIAL MARKET FOR CONDOMS, HIV TESTING, AND OTHER HEALTH PRODUCTS AND SERVICES. BY MAKING PRODUCTS ACCESSIBLE TO EVERYDAY CONSUMERS WHO CAN AFFORD THEM, THE PROJECT FREES THE GOVERNMENT TO FOCUS FUNDING ON THOSE WHO CANNOT.IN MYANMAR, PATH IS ALSO ADDRESSING MICRONUTRIENT DEFICIENCIES THROUGH THE INTRODUCTION OF FORTIFIED RICE. WE ARE WORKING WITH PARTNERS TO SUPPORT FAVORABLE POLICY, DEVELOP LOCAL PRODUCTION, IMPROVE DISTRIBUTION, AND BUILD MARKETING AND PROMOTION CHANNELS.IN SENEGAL, WE ARE PARTNERING CLOSELY WITH THE NATIONAL MINISTRY OF HEALTH TO STRENGTHEN THE COUNTRY'S HEALTH SYSTEMS. THIS INCLUDES BUILDING THE CAPACITY OF INDIVIDUAL MINISTRY OF HEALTH DIVISIONS AND IMPROVING KEY HEALTH SYSTEMS AND PROCESSES. IN 2014, OUR RELATIONSHIPS AND EXPERIENCE PROVED CRUCIAL TO THE FIGHT AGAINST EBOLA. PATH PLAYED A MAJOR ROLE IN SUPPORTING THE MINISTRY OF HEALTH TO SET UP A NATIONAL EMERGENCY OPERATIONS CENTER AND DEVELOP TREATMENT GUIDELINES, SURVEILLANCE PROCESSES, AND OTHER SYSTEMS AND PROCEDURES TO RESPOND TO THE THREAT.PATH'S MALARIA CONTROL AND ELIMINATION PROGRAM (MACEPA) CONTINUES TO SUPPORT THE COUNTRY AS IT DRAWS CLOSER TO ELIMINATING MALARIA. IN SENEGAL, WE ARE BUILDING THE SURVEILLANCE SYSTEMS NECESSARY TO FIND AND TREAT NEW CASES QUICKLY-BREAKING THE CYCLE OF TRANSMISSION. THIS INCLUDES SUPPORTING FIELD WORKERS WHO GO HOUSE TO HOUSE, TESTING PEOPLE AND INVESTIGATING CASES. WITH PATH HELP, WORKERS USE AN ELECTRONIC SYSTEM TO UPLOAD THEIR FINDINGS TO A COMMON DATABASE. THE RESULT IS A REAL-TIME CASE MAP, ALLOWING LEADERS TO BETTER PLAN AND TARGET RESOURCES AND RESPOND MORE QUICKLY TO POTENTIAL OUTBREAKS.IN ADDITION, WE ARE HELPING TO BRING MODERN FAMILY PLANNING TO THE ESTIMATED 40 PERCENT OF SENEGALESE WOMEN WITHOUT ACCESS. THIS YEAR, SENEGAL WAS ONE OF FOUR COUNTRIES WHERE SAYANA PRESS, A NEW FORM OF A POPULAR INJECTABLE CONTRACEPTIVE DEVELOPED BY PATH AND PARTNERS, WAS LAUNCHED. THE PRODUCT WILL BRING MILLIONS OF WOMEN A SAFE, EFFECTIVE NEW CHOICE IN FAMILY PLANNING.IN ZAMBIA, PATH IS STRENGTHENING NATIONAL HEALTH SYSTEMS AND TARGETING KEY HEALTH THREATS. MACEPA CONTINUED TO PARTNER WITH THE GOVERNMENT TO STRENGTHEN THE MALARIA PROGRAM THROUGH FIELD-TESTING NEW STRATEGIES TO DECREASE MALARIA TRANSMISSION, EFFICIENT PLANNING, SURVEILLANCE, AND OTHER AREAS CRUCIAL TO ELIMINATION. THROUGH THE MALARIACARE EFFORT, WE TRAINED LABORATORY WORKERS AND CLINICIANS TO TEST FOR AND TREAT MALARIA AND PROVIDED ONGOING SUPERVISION. OUR EFFORTS TO IMPROVE THE HEALTH OF WOMEN AND CHILDREN INCLUDED AN ASSESSMENT OF OPPORTUNITIES TO STOP THE TRANSMISSION OF SYPHILIS FROM MOTHERS TO BABIES. IN COLLABORATION WITH OTHER ADVOCATES, OUR ADVOCACY TEAM PERSUADED THE GOVERNMENT OF ZAMBIA TO ADOPT TWO NEW NATIONAL POLICIES THAT WILL IMPROVE THE HEALTH OF NEWBORNS BY GUIDING HEALTH WORKERS AND ENCOURAGING INCREASED GOVERNMENT FUNDING. TO IMPROVE IMMUNIZATION, WE WORKED THROUGH GAVI, THE VACCINE ALLIANCE, TO EVALUATE KEY BARRIERS TO IMMUNIZATION IN ZAMBIA. AND THROUGH THE BID INITIATIVE, WE CONTINUED A BROAD PORTFOLIO OF WORK TO IMPROVE THE COLLECTION AND USE OF HIGH-QUALITY IMMUNIZATION DATA. WORKING WITH OTHER PARTNERS, WE ALSO DEMONSTRATED THAT THE HPV VACCINE, WHICH CAN HELP PREVENT CERVICAL CANCER, CAN BE SUCCESSFULLY ADMINISTERED TO ADOLESCENT GIRLS WHO ATTEND SCHOOL. FINALLY, THE PATH-LED THRIVE PROJECT IMPROVED NUTRITION FOR PEOPLE LIVING WITH HIV/AIDS, PREGNANT WOMEN, AND ORPHANS AND VULNERABLE CHILDREN IN FOUR PROVINCES. WE TRAINED HEALTH WORKERS IN NUTRITION ASSESSMENT, COUNSELING, AND SUPPORT, AND WE INCREASED ACCESS TO KEY PRODUCTS AND SERVICES. IN 2014, FOR EXAMPLE, WE WORKED WITH OUR PARTNERS TO EXPAND THE AVAILABILITY AND MARKET VIABILITY OF HIGH-ENERGY PROTEIN SUPPLEMENT, OR "HEPS"-A NUTRIENT-RICH PORRIDGE. WE INCREASED HEALTH WORKERS' COMFORT WITH HEPS, RAISED PRODUCTION STANDARDS, AND ARE EXPLORING SUSTAINABLE MARKETING AND DISTRIBUTION. | Desc |
Prog Srvc Accom Acty Other ProgSrvcAccomActyOtherGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Expense | $10,076,043 | ExpenseAmt |
| Grant | $3,539,407 | GrantAmt |
| Revenue | $20,545 | RevenueAmt |
| Desc | OTHER PROGRAM SERVICES: PATH'S ADVOCACY AND PUBLIC POLICY PROGRAM WORKS IN THE UNITED STATES; WITH MULTILATERAL HEALTH LEADERS ENGAGED IN GLOBAL POLICY AND PLANNING; AND WITH COUNTRIES AND COMMUNITIES AROUND THE WORLD. WE HELP POLICYMAKERS UNDERSTAND ISSUES AND MOTIVATE THEM TO COMMIT FUNDING, CRAFT POLICIES, AND SPONSOR INITIATIVES TO STRENGTHEN GLOBAL HEALTH EFFORTS. IN 2014, WE LED ADVOCACY EFFORTS FOR THE INCLUSION OF RESEARCH AND DEVELOPMENT (R&D) IN THE POST-2015 DEVELOPMENT AGENDA, AS WELL AS ENSURING SUPPORT FOR GLOBAL HEALTH R&D IN THE UNITED STATES AND EUROPE. OUR PROJECT TO PROVIDE ADVOCACY SUPPORT IN KEY PARTNER COUNTRIES SUCCEEDED IN ADVANCING HEALTH POLICIES WITH THE POTENTIAL TO IMPROVE THE HEALTH OF WOMEN AND CHILDREN. FOR EXAMPLE, IN THE INDIAN STATE OF UTTAR PRADESH, PATH WORKED WITH THE GOVERNMENT TO HELP APPROVE POLICIES THAT WOULD PROVIDE EMERGENCY TRANSPORT FOR WOMEN IN LABOR. INFANT AND MATERNAL MORTALITY RATES ARE HIGH IN THE STATE, IN PART DUE TO LACK OF TRANSPORTATION TO HOSPITALS. PATH'S ADVOCACY EFFORTS LED TO THE DEVELOPMENT OF AN EMERGENCY MEDICAL TRANSPORTATION FRAMEWORK THAT WILL HELP SAVE LIVES.MARKET DYNAMICS: OVER THE PAST YEAR, PATH ALSO ESTABLISHED A FORMAL MARKET DYNAMICS DEPARTMENT. MARKET DYNAMICS WORK ENCOMPASSES EFFORTS TO CHARACTERIZE MARKETS, ASSESS SHORTCOMINGS, AND DESIGN MARKET-BASED INTERVENTIONS TO IMPROVE HEALTH OUTCOMES. THIS WORK COMPLEMENTS PATH'S OTHER EFFORTS, SUCH AS PRODUCT DEVELOPMENT; BUILDS UPON OUR EXISTING STRENGTH IN COMMERCIALIZATION; ALIGNS EXPERTISE ACROSS TEAMS; AND EXPANDS OUR CAPACITY TO ADDRESS MARKET-BASED ISSUES. THE DEPARTMENT IS CURRENTLY LEADING WORK ON MALARIA DRUG SUPPLY STRATEGIES AND SUPPORTING OTHER PATH PROJECTS, INCLUDING ASSESSING MARKETS FOR SEVERAL NOVEL DIAGNOSTICS (FOR EXAMPLE, MALARIA POINT-OF-CARE DIAGNOSTICS) AND ADVOCATING FOR MARKET-BASED SOLUTIONS TO IMPROVE ACCESS TO MATERNAL, NEWBORN, AND CHILD HEALTH PRODUCTS. SPECIAL INITIATIVES: PATH IS ENGAGED IN A VARIETY OF PROJECTS THAT GALVANIZE OUR EXPERTISE AND RESOURCES AND THAT OF OUR GLOBAL PARTNERS TO SAVE MORE LIVES, MORE QUICKLY. THESE SPECIAL INITIATIVES INCREASE OUR IMPACT BY ALIGNING DIVERSE EFFORTS, BRINGING US CLOSER TO A WORLD WHERE HEALTH IS IN REACH FOR EVERY PERSON, NO MATTER WHERE THEY LIVE.OUR MALARIA CENTER OF EXCELLENCE, FOR EXAMPLE, COORDINATES WORK ACROSS OUR INNOVATION PLATFORMS (VACCINES, DRUGS, DIAGNOSTICS, DEVICES, AND SYSTEMS AND SERVICE INNOVATIONS) TO COMBAT MALARIA EVEN MORE EFFECTIVELY AND AGGRESSIVELY. BY ALIGNING AND FOCUSING OUR STRENGTHS, THE INITIATIVE WILL ACCELERATE MOMENTUM TOWARD ACHIEVING THE AUDACIOUS GOAL OF A WORLD WITHOUT MALARIA.IN 2014, WE ALSO LAUNCHED THE PATH-LED INNOVATION COUNTDOWN 2030 (IC2030) INITIATIVE. IC2030 IS REIMAGINING WHAT IS POSSIBLE IN GLOBAL HEALTH. IT AIMS TO IDENTIFY, EVALUATE, AND SHOWCASE HIGH-IMPACT TECHNOLOGIES AND IDEAS THAT CAN TRANSFORM GLOBAL HEALTH BY 2030. BY ENGAGING ENTREPRENEURS, INVESTORS, INNOVATORS, AND EXPERTS ACROSS SECTORS AND AROUND THE WORLD, THE PROJECT AIMS TO HELP DRIVE DECISION-MAKING AND INVESTMENTS IN GAME-CHANGING INNOVATIONS AND ACCELERATE PROGRESS TOWARD ACHIEVING THE UNITED NATIONS SUSTAINABLE DEVELOPMENT GOALS AND RELATED HEALTH TARGETS.PATH'S GLOBAL HEALTH INNOVATION HUB ALSO CONTINUES TO IMPROVE ACCESS TO HEALTH SOLUTIONS. THE HUB SUPPORTS LOCAL INNOVATORS IN COUNTRIES AROUND THE WORLD. DRAWING ON OUR EXPERTISE IN BRINGING TOGETHER THE BEST MINDS FROM ACROSS PUBLIC AND PRIVATE SECTORS, WE HELP INNOVATORS OVERCOME HURDLES-WHETHER IN PRODUCT DESIGN, CLINICAL VALIDATION, COMMERCIALIZATION, OR MARKET DEVELOPMENT-AND GET THEIR SOLUTIONS TO MORE PEOPLE IN RESOURCE-LIMITED COMMUNITIES. IN 2014, WE LAUNCHED THE HUB IN SOUTH AFRICA, WHERE WE STRENGTHENED OUR PARTNERSHIPS WITH SCIENTISTS, ENTREPRENEURS, COMPANIES, AND INVESTORS FOCUSED ON GLOBAL HEALTH INNOVATIONS. WE ALSO ESTABLISHED THE FUNDING NECESSARY TO LAUNCH A HUB IN INDIA IN 2015.IN 2014, IN RECOGNITION OF PATH'S LEADING ROLE IN HEALTH INNOVATION, THE BILL & MELINDA GATES FOUNDATION PROVIDED A GENEROUS INNOVATION FUND (IF) GRANT. THE GRANT WAS CREATED TO INSPIRE AND SUPPORT PATH TEAMS' BEST IDEAS AND CREATIVITY. AFTER SOLICITING IDEAS FROM ACROSS PATH, CREATING A SHORT LIST, AND INVITING STAFF TO VOTE, A PATH INNOVATION FUND TASK FORCE AND OUR EXECUTIVE TEAM SELECTED NINE INNOVATIONS FOR FUNDING. THROUGHOUT 2014, THE GRANT ADVANCED RESEARCH AND WORK TOWARD POTENTIAL SOLUTIONS IN NUTRITION, DIAGNOSTICS, MALARIA, VACCINES, AND OTHER HEALTH AREAS. | Desc |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Other Prog Srvc Expense | $10,076,043 | TotalOtherProgSrvcExpenseAmt |
| Total Other Prog Srvc Grant | $3,539,407 | TotalOtherProgSrvcGrantAmt |
| Total Other Prog Srvc Revenue | $20,545 | TotalOtherProgSrvcRevenueAmt |
| Total Program Service Expenses | $227,364,723 | TotalProgramServiceExpensesAmt |
| Described In Section501c3 | Yes (1) | DescribedInSection501c3Ind |
| Schedule B Required | Yes (1) | ScheduleBRequiredInd |
| Political Campaign Acty | 0 | PoliticalCampaignActyInd |
| Lobbying Activities | Yes (1) | LobbyingActivitiesInd |
| Subject To Proxy Tax | 0 | SubjectToProxyTaxInd |
| Donor Advised Fund | 0 | DonorAdvisedFundInd |
| Conservation Easements | 0 | ConservationEasementsInd |
| Collections Of Art | 0 | CollectionsOfArtInd |
| Credit Counseling | 0 | CreditCounselingInd |
| Temp Or Permanent Endowments | Yes (1) | TempOrPermanentEndowmentsInd |
| Report Land Building Equipment | Yes (1) | ReportLandBuildingEquipmentInd |
| Report Investments Other Sec | 0 | ReportInvestmentsOtherSecInd |
| Report Program Related Invst | 0 | ReportProgramRelatedInvstInd |
| Report Other Assets | 0 | ReportOtherAssetsInd |
| Report Other Liabilities | 0 | ReportOtherLiabilitiesInd |
| Include FIN48 Footnote | 0 | IncludeFIN48FootnoteInd |
| Independent Audit Fincl Stmt | 0 | IndependentAuditFinclStmtInd |
| Consolidated Audit Fincl Stmt | Yes (1) | ConsolidatedAuditFinclStmtInd |
| School Operating | 0 | SchoolOperatingInd |
| Foreign Office | Yes (1) | ForeignOfficeInd |
| Foreign Activities | Yes (1) | ForeignActivitiesInd |
| More Than5000 K To Org | Yes (1) | MoreThan5000KToOrgInd |
| More Than5000 K To Individuals | 0 | MoreThan5000KToIndividualsInd |
| Professional Fundraising | 0 | ProfessionalFundraisingInd |
| Fundraising Activities | Yes (1) | FundraisingActivitiesInd |
| Gaming Activities | 0 | GamingActivitiesInd |
| Operate Hospital | 0 | OperateHospitalInd |
| Grants To Organizations | Yes (1) | GrantsToOrganizationsInd |
| Grants To Individuals | Yes (1) | GrantsToIndividualsInd |
| Schedule J Required | Yes (1) | ScheduleJRequiredInd |
| Tax Exempt Bonds | 0 | TaxExemptBondsInd |
| Engaged In Excess Benefit Trans | 0 | EngagedInExcessBenefitTransInd |
| PY Excess Benefit Trans | 0 | PYExcessBenefitTransInd |
| Loan Outstanding | 0 | LoanOutstandingInd |
| Grant To Related Person | 0 | GrantToRelatedPersonInd |
| Business Rln With Org Mem | 0 | BusinessRlnWithOrgMemInd |
| Business Rln With Fam Mem | 0 | BusinessRlnWithFamMemInd |
| Business Rln With Officer Ent | 0 | BusinessRlnWithOfficerEntInd |
| Deductible Non Cash Contri | Yes (1) | DeductibleNonCashContriInd |
| Deductible Art Contribution | 0 | DeductibleArtContributionInd |
| Terminate Operations | 0 | TerminateOperationsInd |
| Partial Liquidation | 0 | PartialLiquidationInd |
| Disregarded Entity | 0 | DisregardedEntityInd |
| Related Entity | Yes (1) | RelatedEntityInd |
| Related Organization Ctrl Ent | Yes (1) | RelatedOrganizationCtrlEntInd |
| Transaction With Control Ent | Yes (1) | TransactionWithControlEntInd |
| Trnsfr Exmpt Non Chrtbl Rltd Org | 0 | TrnsfrExmptNonChrtblRltdOrgInd |
| Activities Conducted Prtshp | 0 | ActivitiesConductedPrtshpInd |
| Schedule O Required | Yes (1) | ScheduleORequiredInd |
| Info In Schedule O Part V | Yes (X) | InfoInScheduleOPartVInd |
| IRP Document | 246 | IRPDocumentCnt |
| IRP Document W2 G | 0 | IRPDocumentW2GCnt |
| Backup Wthld Compliance | Yes (1) | BackupWthldComplianceInd |
| Employee | 746 | EmployeeCnt |
| Employment Tax Returns Filed | Yes (1) | EmploymentTaxReturnsFiledInd |
| Unrelated Bus Incm Over Limit | 0 | UnrelatedBusIncmOverLimitInd |
| Foreign Financial Account | Yes (1) | ForeignFinancialAccountInd |
| Foreign Country | BE | ForeignCountryCd |
| Foreign Country | CB | ForeignCountryCd |
| Foreign Country | CH | ForeignCountryCd |
| Foreign Country | CG | ForeignCountryCd |
| Foreign Country | ET | ForeignCountryCd |
| Foreign Country | FR | ForeignCountryCd |
| Foreign Country | GH | ForeignCountryCd |
| Foreign Country | IN | ForeignCountryCd |
| Foreign Country | MZ | ForeignCountryCd |
| Foreign Country | OC | ForeignCountryCd |
| Foreign Country | NU | ForeignCountryCd |
| Foreign Country | PE | ForeignCountryCd |
| Foreign Country | SZ | ForeignCountryCd |
| Foreign Country | TZ | ForeignCountryCd |
| Foreign Country | TH | ForeignCountryCd |
| Foreign Country | UG | ForeignCountryCd |
| Foreign Country | KE | ForeignCountryCd |
| Foreign Country | UP | ForeignCountryCd |
| Foreign Country | VM | ForeignCountryCd |
| Foreign Country | ZA | ForeignCountryCd |
| Foreign Country | SG | ForeignCountryCd |
| Foreign Country | SF | ForeignCountryCd |
| Foreign Country | UK | ForeignCountryCd |
| Prohibited Tax Shelter Trans | 0 | ProhibitedTaxShelterTransInd |
| Taxable Party Notification | 0 | TaxablePartyNotificationInd |
| Nondeductible Contributions | 0 | NondeductibleContributionsInd |
| Quid Pro Quo Contributions | Yes (1) | QuidProQuoContributionsInd |
| Quid Pro Quo Contri Discl | Yes (1) | QuidProQuoContriDisclInd |
| Form8282 Property Disposed Of | 0 | Form8282PropertyDisposedOfInd |
| Rcv Fnds To Pay Prsnl Bnft Cntrct | 0 | RcvFndsToPayPrsnlBnftCntrctInd |
| Pay Premiums Prsnl Bnft Cntrct | 0 | PayPremiumsPrsnlBnftCntrctInd |
| Indoor Tanning Services | 0 | IndoorTanningServicesInd |
| Info In Schedule O Part VI | Yes (X) | InfoInScheduleOPartVIInd |
| Governing Body Voting Members | 15 | GoverningBodyVotingMembersCnt |
| Independent Voting Member | 15 | IndependentVotingMemberCnt |
| Family Or Business Rln | 0 | FamilyOrBusinessRlnInd |
| Delegation Of Mgmt Duties | 0 | DelegationOfMgmtDutiesInd |
| Change To Org Documents | 0 | ChangeToOrgDocumentsInd |
| Material Diversion Or Misuse | 0 | MaterialDiversionOrMisuseInd |
| Members Or Stockholders | 0 | MembersOrStockholdersInd |
| Election Of Board Members | 0 | ElectionOfBoardMembersInd |
| Decisions Subject To Approva | 0 | DecisionsSubjectToApprovaInd |
| Minutes Of Governing Body | Yes (1) | MinutesOfGoverningBodyInd |
| Minutes Of Committees | Yes (1) | MinutesOfCommitteesInd |
| Officer Mailing Address | 0 | OfficerMailingAddressInd |
| Local Chapters | 0 | LocalChaptersInd |
| Form990 Provided To Gvrn Body | Yes (1) | Form990ProvidedToGvrnBodyInd |
| Conflict Of Interest Policy | Yes (1) | ConflictOfInterestPolicyInd |
| Annual Disclosure Covered Prsn | Yes (1) | AnnualDisclosureCoveredPrsnInd |
| Regular Monitoring Enfrc | Yes (1) | RegularMonitoringEnfrcInd |
| Whistleblower Policy | Yes (1) | WhistleblowerPolicyInd |
| Document Retention Policy | Yes (1) | DocumentRetentionPolicyInd |
| Compensation Process CEO | Yes (1) | CompensationProcessCEOInd |
| Compensation Process Other | Yes (1) | CompensationProcessOtherInd |
| Investment In Joint Venture | 0 | InvestmentInJointVentureInd |
| States Where Copy Of Return Is Fld | AZ | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | CA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | CT | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | FL | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | IL | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | MD | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NJ | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NY | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | NC | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | OH | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | OR | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | PA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | TX | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | VA | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | VT | StatesWhereCopyOfReturnIsFldCd |
| States Where Copy Of Return Is Fld | WA | StatesWhereCopyOfReturnIsFldCd |
| Own Website | Yes (X) | OwnWebsiteInd |
| Upon Request | Yes (X) | UponRequestInd |
Books In Care Of Detail BooksInCareOfDetail
Business Name BusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | OLIVIA POLIUS CHIEF FINANCIAL OFFICER | BusinessNameLine1Txt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Phone | 2062853500 | PhoneNum |
US Address USAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | 2201 WESTLAKE AVE SUITE 200 | AddressLine1Txt |
| City | SEATTLE | CityNm |
| State Abbreviation | WA | StateAbbreviationCd |
| ZIP | 98121 | ZIPCd |
Form990 Part VII Section A Form990PartVIISectionAGrp (35 entries)
| TitleTitleTxt | Average Hours Per WeekAverageHoursPerWeekRt | Average Hours Per Week Rltd OrgAverageHoursPerWeekRltdOrgRt | Individual Trustee Or DirectorIndividualTrusteeOrDirectorInd | OfficerOfficerInd | Reportable Comp From OrgReportableCompFromOrgAmt | Reportable Comp From Rltd OrgReportableCompFromRltdOrgAmt | Other CompensationOtherCompensationAmt | Key EmployeeKeyEmployeeInd | Highest Compensated EmployeeHighestCompensatedEmployeeInd |
|---|---|---|---|---|---|---|---|---|---|
| DEAN ALLEN | |||||||||
| BOARD CHAIR | 2.00 | 0.00 | Yes (X) | Yes (X) | $0 | $0 | $0 | ||
| GEORGE GOTSADZE | |||||||||
| BOARD VICE CHAIR | 2.00 | 0.00 | Yes (X) | Yes (X) | $0 | $0 | $0 | ||
| EIVOR HALKJAER | |||||||||
| BOARD SECRETARY | 2.00 | 0.00 | Yes (X) | Yes (X) | $0 | $0 | $0 | ||
| DAVID KING | |||||||||
| BOARD TREASURER | 2.00 | 0.00 | Yes (X) | Yes (X) | $0 | $0 | $0 | ||
| JO ADDY | |||||||||
| DIRECTOR | 2.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| KOFI AMEGASHIE | |||||||||
| DIRECTOR | 2.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| PHYLLIS CAMPBELL | |||||||||
| DIRECTOR | 2.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| ALEX CHIKA EZAH | |||||||||
| DIRECTOR | 2.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| RAJENDRA VATTIKUTI | |||||||||
| DIRECTOR | 2.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| KEVIN REILLY | |||||||||
| DIRECTOR | 2.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| VINCENT MCGEE | |||||||||
| DIRECTOR | 2.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| FELIX OLALE | |||||||||
| DIRECTOR | 2.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| TSITSI MASIYIWA | |||||||||
| DIRECTOR (BEGAN 12/17/14) | 2.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| IREENA VITTAL | |||||||||
| DIRECTOR (BEGAN 12/17/14) | 2.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| YEHONG ZHANG | |||||||||
| DIRECTOR (BEGAN 12/17/14) | 2.00 | 0.00 | Yes (X) | $0 | $0 | $0 | |||
| STEVEN B DAVIS | |||||||||
| PRESIDENT AND CEO | 38.00 | 2.00 | Yes (X) | $569,984 | $0 | $43,512 | |||
| MICHAEL B KOLLINS | |||||||||
| CHIEF OPERATING OFFICER | 40.00 | 0.00 | Yes (X) | $275,774 | $0 | $40,645 | |||
| OLIVIA POLIUS | |||||||||
| CHIEF FINANCIAL OFFICER | 38.00 | 2.00 | Yes (X) | $255,770 | $0 | $39,644 | |||
| DAVID C KASLOW | |||||||||
| VP, PRODUCT DEVELOPMENT | 38.00 | 2.00 | $378,301 | $0 | $41,432 | Yes (X) | |||
| JOHN W BOSLEGO | |||||||||
| GLOBAL PROG. LDR II (UNTIL 12/2/14) | 40.00 | 0.00 | $328,552 | $0 | $40,363 | Yes (X) | |||
| AMIE E BATSON | |||||||||
| CHIEF STRATEGY OFFICER | 39.00 | 1.00 | $275,229 | $0 | $32,472 | Yes (X) | |||
| RIKKA E TRANGSRUD | |||||||||
| COUNTRY PROGRAM LEADER II | 40.00 | 0.00 | $272,382 | $0 | $31,254 | Yes (X) | |||
| ASHLEY J BIRKETT | |||||||||
| GLOBAL PROGRAM LEADER I | 40.00 | 0.00 | $271,008 | $0 | $26,224 | Yes (X) | |||
| KATHLEEN M NEUZIL | |||||||||
| GLOBAL PROGRAM LEADER I | 40.00 | 0.00 | $255,164 | $0 | $35,920 | Yes (X) | |||
| DANIEL LASTER | |||||||||
| GENERAL COUNSEL | 38.00 | 2.00 | $250,848 | $0 | $39,180 | Yes (X) | |||
| ANURAG PRABHAKAR MAIRAL | |||||||||
| GLOBAL PROGRAM LEADER I | 40.00 | 0.00 | $236,991 | $0 | $38,525 | Yes (X) | |||
| KATHRYN A O'DRISCOLL | |||||||||
| CHIEF H.R. OFFICER | 40.00 | 0.00 | $223,925 | $0 | $37,734 | Yes (X) | |||
| AYORINDE ALBERT AJAYI | |||||||||
| VP, INTL. DEV. (UNTIL 9/10/14) | 40.00 | 0.00 | $222,691 | $0 | $30,722 | Yes (X) | |||
| JANE E HUTCHINGS | |||||||||
| GLOBAL PROGRAM LEADER I | 40.00 | 0.00 | $217,735 | $0 | $38,569 | Yes (X) | |||
| CARLOS CLINTON CAMPBELL | |||||||||
| GLOBAL PROGRAM LEADER I | 40.00 | 0.00 | $206,490 | $0 | $22,662 | Yes (X) | |||
| JOHN SKIBIAK | |||||||||
| ASSOCIATE DIRECTOR II | 40.00 | 0.00 | $388,090 | $0 | $35,254 | Yes (X) | |||
| GRANT N COLFAX | |||||||||
| GLOBAL PROGRAM LEADER I | 40.00 | 0.00 | $284,055 | $0 | $29,573 | Yes (X) | |||
| TRAD M HATTON | |||||||||
| CHIEF OF PARTY | 40.00 | 0.00 | $272,736 | $0 | $25,971 | Yes (X) | |||
| RAMONDA ANNE BYRKIT | |||||||||
| COUNTRY PROGRAM LEADER I | 40.00 | 0.00 | $254,930 | $0 | $32,356 | Yes (X) | |||
| DUNCAN OWENS EARLE | |||||||||
| ASSOCIATE DIRECTOR II | 40.00 | 0.00 | $249,848 | $0 | $32,227 | Yes (X) | |||
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Reportable Comp From Org | $5,690,503 | TotalReportableCompFromOrgAmt |
| Tot Reportable Comp Rltd Org | $0 | TotReportableCompRltdOrgAmt |
| Total Other Compensation | $694,239 | TotalOtherCompensationAmt |
| Indiv Rcvd Greater Than100 K | 237 | IndivRcvdGreaterThan100KCnt |
| Former Ofcr Employees Listed | 0 | FormerOfcrEmployeesListedInd |
| Total Comp Greater Than150 K | Yes (1) | TotalCompGreaterThan150KInd |
| Compensation From Other Srcs | 0 | CompensationFromOtherSrcsInd |
Contractor Compensation ContractorCompensationGrp (5 entries)
| Address Line1ContractorAddress/USAddress/AddressLine1Txt | CityContractorAddress/USAddress/CityNm | State AbbreviationContractorAddress/USAddress/StateAbbreviationCd | ZIPContractorAddress/USAddress/ZIPCd | ServicesServicesDesc | CompensationCompensationAmt |
|---|---|---|---|---|---|
| AEROTEK INC | |||||
| 7301 PARKWAY DRIVE S | HANOVER | MD | 21076 | STAFFING SERVICES | $811,419 |
| WIDENET CONSULTING GROUP LLC | |||||
| 11400 SE 6TH ST 130 | BELLEVUE | WA | 98004 | CONSULTING | $721,903 |
| NYHUS COMMUNICATIONS LLC | |||||
| 1525 4TH AVE 400 | SEATTLE | WA | 98104 | CONSULTING | $470,845 |
| SLALOM LLC | |||||
| 821 2ND AVE STE 1900 | SEATTLE | WA | 98124 | CONSULTING | $360,018 |
| RESOURCES GLOBAL PROFESSIONALS | |||||
| 17101 ARMSTRONG AVE 100 | IRVINE | CA | 90074 | STAFFING SERVICES | $320,038 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Cntrct Rcvd Greater Than100 K | 21 | CntrctRcvdGreaterThan100KCnt |
| Fundraising | $35,220 | FundraisingAmt |
| Related Organizations | $22,856,948 | RelatedOrganizationsAmt |
| Government Grants | $79,718,238 | GovernmentGrantsAmt |
| All Other Contributions | $184,281,129 | AllOtherContributionsAmt |
| Noncash Contributions | $722,100 | NoncashContributionsAmt |
| Total Contributions | $286,891,535 | TotalContributionsAmt |
Program Service Revenue ProgramServiceRevenueGrp (3 entries)
| DescDesc | BusinessBusinessCd | Total Revenue ColumnTotalRevenueColumnAmt | Related Or Exempt Func IncomeRelatedOrExemptFuncIncomeAmt |
|---|---|---|---|
| HONORARIUM | 900099 | $15,328 | $15,328 |
| CONSULTANCIES | 541900 | $5,967 | $5,967 |
| SALES | 900099 | $1,083 | $1,083 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Program Service Revenue | $22,378 | TotalProgramServiceRevenueAmt |
Investment Income InvestmentIncomeGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $1,370,599 | TotalRevenueColumnAmt |
| Exclusion | $1,370,599 | ExclusionAmt |
Gross Amount Sales Assets GrossAmountSalesAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | $57,687,644 | SecuritiesAmt |
| Other | $97,000 | OtherAmt |
Less Cost Oth Basis Sales Expnss LessCostOthBasisSalesExpnssGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | $57,219,488 | SecuritiesAmt |
| Other | $370,357 | OtherAmt |
Gain Or Loss GainOrLossGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Securities | $468,156 | SecuritiesAmt |
| Other | -$273,357 | OtherAmt |
Net Gain Or Loss Investments NetGainOrLossInvestmentsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $194,799 | TotalRevenueColumnAmt |
| Exclusion | $194,799 | ExclusionAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Fundraising Gross Income | $141,900 | FundraisingGrossIncomeAmt |
| Contri Rpt Fundraising Event | $35,220 | ContriRptFundraisingEventAmt |
| Fundraising Direct Expenses | $105,259 | FundraisingDirectExpensesAmt |
Net Incm From Fundraising Evt NetIncmFromFundraisingEvtGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $36,641 | TotalRevenueColumnAmt |
| Exclusion | $36,641 | ExclusionAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Gaming Gross Income | $5,100 | GamingGrossIncomeAmt |
| Gaming Direct Expenses | $3,239 | GamingDirectExpensesAmt |
Net Income From Gaming NetIncomeFromGamingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $1,861 | TotalRevenueColumnAmt |
| Exclusion | $1,861 | ExclusionAmt |
Other Revenue Misc OtherRevenueMiscGrp (3 entries)
| DescDesc | BusinessBusinessCd | Total Revenue ColumnTotalRevenueColumnAmt | ExclusionExclusionAmt |
|---|---|---|---|
| REIMBURSEMENTS | 900099 | $519,092 | $519,092 |
| OTHER | 900099 | $141,068 | $141,068 |
| GAIN-FOREIGN EXCH. | 900099 | $102,971 | $102,971 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Revenue Total | $763,131 | OtherRevenueTotalAmt |
Total Revenue TotalRevenueGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Revenue Column | $289,280,944 | TotalRevenueColumnAmt |
| Related Or Exempt Func Income | $22,378 | RelatedOrExemptFuncIncomeAmt |
| Unrelated Business Revenue | $0 | UnrelatedBusinessRevenueAmt |
| Exclusion | $2,367,031 | ExclusionAmt |
Grants To Domestic Orgs GrantsToDomesticOrgsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $30,755,257 | TotalAmt |
| Program Services | $30,755,257 | ProgramServicesAmt |
Grants To Domestic Individuals GrantsToDomesticIndividualsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $250,504 | TotalAmt |
| Program Services | $250,504 | ProgramServicesAmt |
Foreign Grants ForeignGrantsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $40,866,596 | TotalAmt |
| Program Services | $40,866,596 | ProgramServicesAmt |
Comp Current Ofcr Directors CompCurrentOfcrDirectorsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $4,779,705 | TotalAmt |
| Program Services | $2,263,520 | ProgramServicesAmt |
| Management And General | $2,493,243 | ManagementAndGeneralAmt |
| Fundraising | $22,942 | FundraisingAmt |
Other Salaries And Wages OtherSalariesAndWagesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $80,749,839 | TotalAmt |
| Program Services | $48,180,820 | ProgramServicesAmt |
| Management And General | $31,404,940 | ManagementAndGeneralAmt |
| Fundraising | $1,164,079 | FundraisingAmt |
Pension Plan Contributions PensionPlanContributionsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $7,616,783 | TotalAmt |
| Management And General | $7,616,783 | ManagementAndGeneralAmt |
Other Employee Benefits OtherEmployeeBenefitsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $11,283,728 | TotalAmt |
| Program Services | $1,009,697 | ProgramServicesAmt |
| Management And General | $10,274,031 | ManagementAndGeneralAmt |
Payroll Taxes PayrollTaxesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $6,401,023 | TotalAmt |
| Program Services | $231,905 | ProgramServicesAmt |
| Management And General | $6,169,118 | ManagementAndGeneralAmt |
Fees For Services Legal FeesForServicesLegalGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $311,708 | TotalAmt |
| Program Services | $86,294 | ProgramServicesAmt |
| Management And General | $225,414 | ManagementAndGeneralAmt |
Fees For Services Accounting FeesForServicesAccountingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $388,147 | TotalAmt |
| Program Services | $23,687 | ProgramServicesAmt |
| Management And General | $364,460 | ManagementAndGeneralAmt |
Fees For Services Lobbying FeesForServicesLobbyingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $113,288 | TotalAmt |
| Program Services | $26,136 | ProgramServicesAmt |
| Management And General | $87,152 | ManagementAndGeneralAmt |
Fees For Srvc Invst Mgmnt Fees FeesForSrvcInvstMgmntFeesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $266,421 | TotalAmt |
| Management And General | $266,421 | ManagementAndGeneralAmt |
Fees For Services Other FeesForServicesOtherGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $10,043,281 | TotalAmt |
| Program Services | $6,516,284 | ProgramServicesAmt |
| Management And General | $3,455,486 | ManagementAndGeneralAmt |
| Fundraising | $71,511 | FundraisingAmt |
Advertising AdvertisingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $314,518 | TotalAmt |
| Program Services | $151,918 | ProgramServicesAmt |
| Management And General | $153,915 | ManagementAndGeneralAmt |
| Fundraising | $8,685 | FundraisingAmt |
Office Expenses OfficeExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $4,658,968 | TotalAmt |
| Program Services | $3,542,303 | ProgramServicesAmt |
| Management And General | $1,070,422 | ManagementAndGeneralAmt |
| Fundraising | $46,243 | FundraisingAmt |
Information Technology InformationTechnologyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $1,020,432 | TotalAmt |
| Program Services | $491,233 | ProgramServicesAmt |
| Management And General | $481,825 | ManagementAndGeneralAmt |
| Fundraising | $47,374 | FundraisingAmt |
Royalties RoyaltiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $48,980 | TotalAmt |
| Program Services | $48,980 | ProgramServicesAmt |
Occupancy OccupancyGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $10,248,321 | TotalAmt |
| Program Services | $625,861 | ProgramServicesAmt |
| Management And General | $9,622,460 | ManagementAndGeneralAmt |
Travel TravelGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $18,020,598 | TotalAmt |
| Program Services | $15,719,728 | ProgramServicesAmt |
| Management And General | $2,215,508 | ManagementAndGeneralAmt |
| Fundraising | $85,362 | FundraisingAmt |
Conferences Meetings ConferencesMeetingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $6,494,926 | TotalAmt |
| Program Services | $5,991,886 | ProgramServicesAmt |
| Management And General | $341,775 | ManagementAndGeneralAmt |
| Fundraising | $161,265 | FundraisingAmt |
Interest InterestGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $75,698 | TotalAmt |
| Management And General | $75,698 | ManagementAndGeneralAmt |
Depreciation Depletion DepreciationDepletionGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $2,489,286 | TotalAmt |
| Program Services | $179,178 | ProgramServicesAmt |
| Management And General | $2,310,108 | ManagementAndGeneralAmt |
Insurance InsuranceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $339,568 | TotalAmt |
| Program Services | $22,259 | ProgramServicesAmt |
| Management And General | $317,309 | ManagementAndGeneralAmt |
Other Expenses OtherExpensesGrp (4 entries)
| DescDesc | TotalTotalAmt | Program ServicesProgramServicesAmt | Management And GeneralManagementAndGeneralAmt | FundraisingFundraisingAmt |
|---|---|---|---|---|
| SUBCONTRACTS | $25,037,206 | $23,859,661 | $585,746 | $591,799 |
| EQUIP RENT & MAINT | $5,833,787 | $4,819,336 | $977,047 | $37,404 |
| FACILITIES ALLOC | $0 | $9,953,020 | -$10,314,538 | $361,518 |
| LEAVE & BENS ALLOC | $0 | $26,131,638 | -$26,759,258 | $627,620 |
All Other Expenses AllOtherExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $8,215,280 | TotalAmt |
| Program Services | $5,617,022 | ProgramServicesAmt |
| Management And General | $2,566,983 | ManagementAndGeneralAmt |
| Fundraising | $31,275 | FundraisingAmt |
Total Functional Expenses TotalFunctionalExpensesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total | $276,623,848 | TotalAmt |
| Program Services | $227,364,723 | ProgramServicesAmt |
| Management And General | $46,002,048 | ManagementAndGeneralAmt |
| Fundraising | $3,257,077 | FundraisingAmt |
Cash Non Interest Bearing CashNonInterestBearingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $13,397,133 | BOYAmt |
| EOY | $27,155,160 | EOYAmt |
Savings And Temp Cash Invst SavingsAndTempCashInvstGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $40,026,863 | BOYAmt |
| EOY | $85,106,641 | EOYAmt |
Pledges And Grants Receivable PledgesAndGrantsReceivableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $254,302,858 | BOYAmt |
| EOY | $225,750,342 | EOYAmt |
Accounts Receivable AccountsReceivableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $7,771,974 | BOYAmt |
| EOY | $12,072,596 | EOYAmt |
Prepaid Expenses Defrd Charges PrepaidExpensesDefrdChargesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $2,850,259 | BOYAmt |
| EOY | $2,917,489 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Land Bldg Equip Cost Or Other Bss | $33,563,347 | LandBldgEquipCostOrOtherBssAmt |
| Land Bldg Equip Accum Deprec | $16,642,765 | LandBldgEquipAccumDeprecAmt |
Land Bldg Equip Basis Net LandBldgEquipBasisNetGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $18,577,714 | BOYAmt |
| EOY | $16,920,582 | EOYAmt |
Investments Pub Traded Sec InvestmentsPubTradedSecGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $148,068,288 | BOYAmt |
| EOY | $125,648,641 | EOYAmt |
Intangible Assets IntangibleAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $223,973 | BOYAmt |
| EOY | $44,795 | EOYAmt |
Other Assets Total OtherAssetsTotalGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $603,218 | BOYAmt |
| EOY | $0 | EOYAmt |
Total Assets TotalAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $485,822,280 | BOYAmt |
| EOY | $495,616,246 | EOYAmt |
Accounts Payable Accr Expnss AccountsPayableAccrExpnssGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $52,731,771 | BOYAmt |
| EOY | $50,802,396 | EOYAmt |
Mortg Notes Pybl Scrd Invst Prop MortgNotesPyblScrdInvstPropGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $4,335,893 | BOYAmt |
| EOY | $3,404,022 | EOYAmt |
Total Liabilities TotalLiabilitiesGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $57,067,664 | BOYAmt |
| EOY | $54,206,418 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Organization Follows SFAS117 | Yes (X) | OrganizationFollowsSFAS117Ind |
Unrestricted Net Assets UnrestrictedNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $21,836,456 | BOYAmt |
| EOY | $19,517,592 | EOYAmt |
Temporarily Rstr Net Assets TemporarilyRstrNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $403,540,565 | BOYAmt |
| EOY | $418,505,291 | EOYAmt |
Permanently Rstr Net Assets PermanentlyRstrNetAssetsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $3,377,595 | BOYAmt |
| EOY | $3,386,945 | EOYAmt |
Total Net Assets Fund Balance TotalNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $428,754,616 | BOYAmt |
| EOY | $441,409,828 | EOYAmt |
Tot Liab Net Assets Fund Balance TotLiabNetAssetsFundBalanceGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| BOY | $485,822,280 | BOYAmt |
| EOY | $495,616,246 | EOYAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Reconcilation Revenue Expnss | $12,657,096 | ReconcilationRevenueExpnssAmt |
| Net Unrlzd Gains Losses Invst | -$1,884 | NetUnrlzdGainsLossesInvstAmt |
| Other Changes In Net Assets | $0 | OtherChangesInNetAssetsAmt |
| Method Of Accounting Accrual | Yes (X) | MethodOfAccountingAccrualInd |
| Accountant Compile Or Review | 0 | AccountantCompileOrReviewInd |
| FS Audited | Yes (1) | FSAuditedInd |
FS Audited Basis FSAuditedBasisGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Consolidated Basis Fincl Stmt | Yes (X) | ConsolidatedBasisFinclStmtInd |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Audit Committee | Yes (1) | AuditCommitteeInd |
| Federal Grant Audit Required | Yes (1) | FederalGrantAuditRequiredInd |
| Federal Grant Audit Performed | Yes (1) | FederalGrantAuditPerformedInd |
Schedule A IRS990ScheduleA
| Field | Value | IRS element (for citing) |
|---|---|---|
| Public Organization170 | Yes (X) | PublicOrganization170Ind |
Gifts Grants Contri Rcvd170 GiftsGrantsContriRcvd170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $152,434,405 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $240,628,741 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $171,536,869 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $260,656,932 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $286,891,535 | CurrentTaxYearAmt |
| Total | $1,112,148,482 | TotalAmt |
Total Calendar Year170 TotalCalendarYear170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $152,434,405 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $240,628,741 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $171,536,869 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $260,656,932 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $286,891,535 | CurrentTaxYearAmt |
| Total | $1,112,148,482 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Substantial Contributors Tot | $362,632,553 | SubstantialContributorsTotAmt |
| Public Support Total170 | $749,515,929 | PublicSupportTotal170Amt |
Gross Investment Income170 GrossInvestmentIncome170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $4,380,066 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $2,797,154 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $2,295,453 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $1,577,831 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $1,370,599 | CurrentTaxYearAmt |
| Total | $12,421,103 | TotalAmt |
Unrelated Business Net Incm170 UnrelatedBusinessNetIncm170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year | $38,502 | CurrentTaxYearAmt |
| Total | $38,502 | TotalAmt |
Other Income170 OtherIncome170Grp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Tax Year Minus4 Years | $1,557,958 | CurrentTaxYearMinus4YearsAmt |
| Current Tax Year Minus3 Years | $502,596 | CurrentTaxYearMinus3YearsAmt |
| Current Tax Year Minus2 Years | $730,742 | CurrentTaxYearMinus2YearsAmt |
| Current Tax Year Minus1 Year | $2,432,891 | CurrentTaxYearMinus1YearAmt |
| Current Tax Year | $763,131 | CurrentTaxYearAmt |
| Total | $5,987,318 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Support | $1,130,595,405 | TotalSupportAmt |
| Gross Receipts Rltd Activities | $172,419 | GrossReceiptsRltdActivitiesAmt |
| Public Support CY170 | 0.66290 | PublicSupportCY170Pct |
| Public Support PY170 | 0.70730 | PublicSupportPY170Pct |
| Thirty Thr Pct Suprt Tests CY170 | Yes (X) | ThirtyThrPctSuprtTestsCY170Ind |
Schedule B IRS990ScheduleB
Contributor Information ContributorInformationGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Contributor | RESTRICTED | ContributorNum |
Contributor Business Name ContributorBusinessName
| Field | Value | IRS element (for citing) |
|---|---|---|
| Business Name Line1 | RESTRICTED | BusinessNameLine1 |
Contributor US Address ContributorUSAddress
| Field | Value | IRS element (for citing) |
|---|---|---|
| Address Line1 | RESTRICTED | AddressLine1 |
| Address Line2 | RESTRICTED | AddressLine2 |
| City | RESTRICTED | City |
| State | RESTRICTED | State |
| ZIP Code | RESTRICTED | ZIPCode |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Contributions | RESTRICTED | TotalContributionsAmt |
Schedule C IRS990ScheduleC
Total Grassroots Lobbying TotalGrassrootsLobbyingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $1,207 | FilingOrganizationsTotalAmt |
Total Direct Lobbying TotalDirectLobbyingGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $221,479 | FilingOrganizationsTotalAmt |
Total Lobbying Expend TotalLobbyingExpendGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $222,686 | FilingOrganizationsTotalAmt |
Other Exempt Purpose Expend OtherExemptPurposeExpendGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $276,401,162 | FilingOrganizationsTotalAmt |
Total Exempt Purpose Expend TotalExemptPurposeExpendGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $276,623,848 | FilingOrganizationsTotalAmt |
Lobbying Nontaxable Amount LobbyingNontaxableAmountGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $1,000,000 | FilingOrganizationsTotalAmt |
Grassroots Nontaxable GrassrootsNontaxableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $250,000 | FilingOrganizationsTotalAmt |
Tot Lbbyng Grassroot Mns Non Tx TotLbbyngGrassrootMnsNonTxGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $0 | FilingOrganizationsTotalAmt |
Tot Lbby Expend Mns Lbbyng Non Tx TotLbbyExpendMnsLbbyngNonTxGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Filing Organizations Total | $0 | FilingOrganizationsTotalAmt |
Avg Lobbying Nontaxable Amount AvgLobbyingNontaxableAmountGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Year Minus3 | $1,000,000 | CurrentYearMinus3Amt |
| Current Year Minus2 | $1,000,000 | CurrentYearMinus2Amt |
| Current Year Minus1 | $1,000,000 | CurrentYearMinus1Amt |
| Current Year | $1,000,000 | CurrentYearAmt |
| Total | $4,000,000 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Lobbying Ceiling | $6,000,000 | LobbyingCeilingAmt |
Avg Total Lobbying Expend AvgTotalLobbyingExpendGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Year Minus3 | $197,270 | CurrentYearMinus3Amt |
| Current Year Minus2 | $193,545 | CurrentYearMinus2Amt |
| Current Year Minus1 | $106,680 | CurrentYearMinus1Amt |
| Current Year | $222,686 | CurrentYearAmt |
| Total | $720,181 | TotalAmt |
Avg Grassroots Nontaxable AvgGrassrootsNontaxableGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Year Minus3 | $250,000 | CurrentYearMinus3Amt |
| Current Year Minus2 | $250,000 | CurrentYearMinus2Amt |
| Current Year Minus1 | $250,000 | CurrentYearMinus1Amt |
| Current Year | $250,000 | CurrentYearAmt |
| Total | $1,000,000 | TotalAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grassroots Ceiling | $1,500,000 | GrassrootsCeilingAmt |
Avg Grassroots Lobbying Expend AvgGrassrootsLobbyingExpendGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Current Year Minus1 | $3,098 | CurrentYearMinus1Amt |
| Current Year | $1,207 | CurrentYearAmt |
| Total | $4,305 | TotalAmt |
Schedule D IRS990ScheduleD
CY Endwmt Fund CYEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $9,016,994 | BeginningYearBalanceAmt |
| Contributions | $9,350 | ContributionsAmt |
| Investment Earnings Or Losses | $768,184 | InvestmentEarningsOrLossesAmt |
| Other Expenditures | $390,340 | OtherExpendituresAmt |
| End Year Balance | $9,404,188 | EndYearBalanceAmt |
CY Minus1 Yr Endwmt Fund CYMinus1YrEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $7,806,786 | BeginningYearBalanceAmt |
| Contributions | $2,550 | ContributionsAmt |
| Investment Earnings Or Losses | $1,503,301 | InvestmentEarningsOrLossesAmt |
| Other Expenditures | $295,643 | OtherExpendituresAmt |
| End Year Balance | $9,016,994 | EndYearBalanceAmt |
CY Minus2 Yr Endwmt Fund CYMinus2YrEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $6,868,767 | BeginningYearBalanceAmt |
| Contributions | $5,392 | ContributionsAmt |
| Investment Earnings Or Losses | $932,627 | InvestmentEarningsOrLossesAmt |
| End Year Balance | $7,806,786 | EndYearBalanceAmt |
CY Minus3 Yr Endwmt Fund CYMinus3YrEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $6,671,532 | BeginningYearBalanceAmt |
| Contributions | $2,700 | ContributionsAmt |
| Investment Earnings Or Losses | $194,535 | InvestmentEarningsOrLossesAmt |
| End Year Balance | $6,868,767 | EndYearBalanceAmt |
CY Minus4 Yr Endwmt Fund CYMinus4YrEndwmtFundGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Beginning Year Balance | $5,943,911 | BeginningYearBalanceAmt |
| Contributions | $1,790 | ContributionsAmt |
| Investment Earnings Or Losses | $725,831 | InvestmentEarningsOrLossesAmt |
| End Year Balance | $6,671,532 | EndYearBalanceAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Board Designated Balance EOY | 0.37000 | BoardDesignatedBalanceEOYPct |
| Prmnnt Endowment Balance EOY | 0.36000 | PrmnntEndowmentBalanceEOYPct |
| Term Endowment Balance EOY | 0.27000 | TermEndowmentBalanceEOYPct |
| Endowments Held Unrelated Org | 0 | EndowmentsHeldUnrelatedOrgInd |
| Endowments Held Related Org | 0 | EndowmentsHeldRelatedOrgInd |
Leasehold Improvements LeaseholdImprovementsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $19,881,814 | OtherCostOrOtherBasisAmt |
| Depreciation | $7,463,795 | DepreciationAmt |
| Book Value | $12,418,019 | BookValueAmt |
Equipment EquipmentGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $10,092,316 | OtherCostOrOtherBasisAmt |
| Depreciation | $7,428,727 | DepreciationAmt |
| Book Value | $2,663,589 | BookValueAmt |
Other Land Buildings OtherLandBuildingsGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Other Cost Or Other Basis | $3,589,217 | OtherCostOrOtherBasisAmt |
| Depreciation | $1,750,243 | DepreciationAmt |
| Book Value | $1,838,974 | BookValueAmt |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total Book Value Land Buildings | $16,920,582 | TotalBookValueLandBuildingsAmt |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART V, LINE 4: | FormAndLineReferenceDesc |
| Explanation | PATH UTILIZES THE INVESTED INTEREST EARNINGS FROM THE ENDOWMENT AS AN IMPORTANT FUNDING SOURCE TO FUND NEW OPPORTUNITIES TO EXPAND ITS REACH AND IMPACT AS AN ORGANIZATION IN THE FIELD OF GLOBAL HEALTH, IN ACCORDANCE WITH PATH'S ENDOWMENT SPENDING POLICY. | ExplanationTxt |
Schedule F IRS990ScheduleF
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Records Maintained | Yes (1) | GrantRecordsMaintainedInd |
Account Activities Outside US AccountActivitiesOutsideUSGrp (47 entries)
| RegionRegionTxt | OfficesOfficesCnt | EmployeeEmployeeCnt | Type Of Activities ConductedTypeOfActivitiesConductedTxt | Region Total ExpendituresRegionTotalExpendituresAmt | Specific Services ProvidedSpecificServicesProvidedTxt |
|---|---|---|---|---|---|
| CENTRAL AMERICA AND THE CARIBBEAN | 1 | 1 | MANAGEMENT & GENERAL | $2,136 | |
| CENTRAL AMERICA AND THE CARIBBEAN | 0 | 0 | PROGRAM SERVICES | $186,353 | PUBLIC HEALTH |
| CENTRAL AMERICA AND THE CARIBBEAN | 0 | 0 | GRANTMAKING | $125,619 | |
| EAST ASIA AND THE PACIFIC | 5 | 53 | MANAGEMENT & GENERAL | $1,468,082 | |
| EAST ASIA AND THE PACIFIC | 0 | 0 | PROGRAM SERVICES | $2,217,011 | PRODUCT DEVELOPMENT |
| EAST ASIA AND THE PACIFIC | 0 | 0 | PROGRAM SERVICES | $2,838,917 | INTERNATIONAL DEVELOPMENT |
| EAST ASIA AND THE PACIFIC | 0 | 0 | PROGRAM SERVICES | $1,088,502 | PUBLIC HEALTH |
| EAST ASIA AND THE PACIFIC | 0 | 0 | PROGRAM SERVICES | $15,144 | OTHER |
| EAST ASIA AND THE PACIFIC | 0 | 0 | GRANTMAKING | $3,457,996 | |
| EUROPE | 3 | 27 | MANAGEMENT & GENERAL | $2,112,395 | |
| EUROPE | 0 | 0 | PROGRAM SERVICES | $21,478,042 | PRODUCT DEVELOPMENT |
| EUROPE | 0 | 0 | PROGRAM SERVICES | $2,932,936 | INTERNATIONAL DEVELOPMENT |
| EUROPE | 0 | 0 | PROGRAM SERVICES | $5,697,140 | PUBLIC HEALTH |
| EUROPE | 0 | 0 | PROGRAM SERVICES | $76,062 | OTHER |
| EUROPE | 0 | 0 | FUNDRAISING | $2,327 | |
| EUROPE | 0 | 0 | GRANTMAKING | $23,005,012 | |
| MIDDLE EAST AND NORTH AFRICA | 0 | 0 | MANAGEMENT & GENERAL | -$405 | |
| MIDDLE EAST AND NORTH AFRICA | 0 | 0 | PROGRAM SERVICES | $136,050 | PUBLIC HEALTH |
| MIDDLE EAST AND NORTH AFRICA | 0 | 0 | GRANTMAKING | $53,201 | |
| NORTH AMERICA | 0 | 0 | MANAGEMENT & GENERAL | $16,521 | |
| NORTH AMERICA | 0 | 0 | PROGRAM SERVICES | $466,724 | PRODUCT DEVELOPMENT |
| NORTH AMERICA | 0 | 0 | PROGRAM SERVICES | $225,042 | PUBLIC HEALTH |
| NORTH AMERICA | 0 | 0 | PROGRAM SERVICES | $2,225 | OTHER |
| NORTH AMERICA | 0 | 0 | GRANTMAKING | $182,219 | |
| RUSSIA & THE NEWLY INDEPENDENT STATES | 1 | 10 | MANAGEMENT & GENERAL | $493,412 | |
| RUSSIA & THE NEWLY INDEPENDENT STATES | 0 | 0 | PROGRAM SERVICES | $748,659 | INTERNATIONAL DEVELOPMENT |
| RUSSIA & THE NEWLY INDEPENDENT STATES | 0 | 0 | PROGRAM SERVICES | $2,362 | PUBLIC HEALTH |
| RUSSIA & THE NEWLY INDEPENDENT STATES | 0 | 0 | PROGRAM SERVICES | $16,252 | OTHER |
| RUSSIA & THE NEWLY INDEPENDENT STATES | 0 | 0 | GRANTMAKING | $54,094 | |
| SOUTH AMERICA | 1 | 2 | MANAGEMENT & GENERAL | $96,818 | |
| SOUTH AMERICA | 0 | 0 | PROGRAM SERVICES | $265,117 | PRODUCT DEVELOPMENT |
| SOUTH AMERICA | 0 | 0 | PROGRAM SERVICES | $466,029 | PUBLIC HEALTH |
| SOUTH AMERICA | 0 | 0 | GRANTMAKING | $475,908 | |
| SOUTH ASIA | 6 | 63 | MANAGEMENT & GENERAL | $1,445,057 | |
| SOUTH ASIA | 0 | 0 | PROGRAM SERVICES | $3,382,369 | PRODUCT DEVELOPMENT |
| SOUTH ASIA | 0 | 0 | PROGRAM SERVICES | $2,871,215 | INTERNATIONAL DEVELOPMENT |
| SOUTH ASIA | 0 | 0 | PROGRAM SERVICES | $528,391 | PUBLIC HEALTH |
| SOUTH ASIA | 0 | 0 | PROGRAM SERVICES | $14,333 | OTHER |
| SOUTH ASIA | 0 | 0 | FUNDRAISING | $19,237 | |
| SOUTH ASIA | 0 | 0 | GRANTMAKING | $3,238,100 | |
| SUB-SAHARAN AFRICA | 18 | 482 | MANAGEMENT & GENERAL | $10,203,240 | |
| SUB-SAHARAN AFRICA | 0 | 0 | PROGRAM SERVICES | $6,843,688 | PRODUCT DEVELOPMENT |
| SUB-SAHARAN AFRICA | 0 | 0 | PROGRAM SERVICES | $18,943,397 | INTERNATIONAL DEVELOPMENT |
| SUB-SAHARAN AFRICA | 0 | 0 | PROGRAM SERVICES | $15,015,023 | PUBLIC HEALTH |
| SUB-SAHARAN AFRICA | 0 | 0 | PROGRAM SERVICES | $539,705 | OTHER |
| SUB-SAHARAN AFRICA | 0 | 0 | FUNDRAISING | $11,056 | |
| SUB-SAHARAN AFRICA | 0 | 0 | GRANTMAKING | $10,274,447 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Subtotal Offices | 6 | SubtotalOfficesCnt |
| Subtotal Employees | 54 | SubtotalEmployeesCnt |
| Continutation Total Office | 29 | ContinutationTotalOfficeCnt |
| Continutation Total Employee | 584 | ContinutationTotalEmployeeCnt |
| Total Office | 35 | TotalOfficeCnt |
| Total Employee | 638 | TotalEmployeeCnt |
| Subtotal Spent | $7,941,764 | SubtotalSpentAmt |
| Continuation Spent | $135,791,396 | ContinuationSpentAmt |
| Total Spent | $143,733,160 | TotalSpentAmt |
Grants To Org Outside US GrantsToOrgOutsideUSGrp (338 entries)
| RegionRegionTxt | Purpose Of GrantPurposeOfGrantTxt | Cash GrantCashGrantAmt | Manner Of Cash DisbursementMannerOfCashDisbursementTxt |
|---|---|---|---|
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $23,661 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $25,764 | CHECK/WIRE |
| EUROPE | PUBLIC HEALTH | $64,952 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $18,610 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $46,567 | CHECK/WIRE |
| SOUTH ASIA | PRODUCT DEVELOPMENT | $335,294 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $8,468 | CHECK/WIRE |
| EUROPE | PRODUCT DEVELOPMENT | $16,347 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | OTHER | $7,802 | CHECK/WIRE |
| SOUTH ASIA | INTERNATIONAL DEVELOPMENT | $498,546 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $296,515 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $16,509 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $12,507 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $29,282 | CHECK/WIRE |
| SOUTH AMERICA | PUBLIC HEALTH | $7,702 | CHECK/WIRE |
| RUSSIA AND NEIGHBORING STATES | INTERNATIONAL DEVELOPMENT | $54,094 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $16,079 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $15,744 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $21,633 | CHECK/WIRE |
| MIDDLE EAST AND NORTH AFRICA | PUBLIC HEALTH | $53,201 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $52,849 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $16,664 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $23,273 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $12,249 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $8,825 | CHECK/WIRE |
| EUROPE | PRODUCT DEVELOPMENT | $132,050 | CHECK/WIRE |
| CENTRAL AMERICA AND THE CARIBBEAN | PUBLIC HEALTH | $74,760 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $7,576 | CHECK/WIRE |
| SOUTH ASIA | INTERNATIONAL DEVELOPMENT | $261,494 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $10,975 | CHECK/WIRE |
| EAST ASIA AND THE PACIFIC | PRODUCT DEVELOPMENT | $5,092 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $8,025 | CHECK/WIRE |
| EAST ASIA AND THE PACIFIC | INTERNATIONAL DEVELOPMENT | $93,851 | CHECK/WIRE |
| EUROPE | PRODUCT DEVELOPMENT | $378,366 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $15,556 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $20,478 | CHECK/WIRE |
| EAST ASIA AND THE PACIFIC | INTERNATIONAL DEVELOPMENT | $8,906 | CHECK/WIRE |
| EAST ASIA AND THE PACIFIC | INTERNATIONAL DEVELOPMENT | $70,553 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $43,357 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $19,614 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $5,329 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $6,599 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $6,088 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $61,455 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $172,097 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $25,057 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $10,475 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $13,440 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $25,917 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $7,072 | CHECK/WIRE |
| EAST ASIA AND THE PACIFIC | PRODUCT DEVELOPMENT | $181,636 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $16,783 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $11,447 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $11,236 | CHECK/WIRE |
| SOUTH AMERICA | PRODUCT DEVELOPMENT | $47,631 | CHECK/WIRE |
| EUROPE | PUBLIC HEALTH | $109,064 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $34,742 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $81,758 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $26,576 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $19,775 | CHECK/WIRE |
| EAST ASIA AND THE PACIFIC | PRODUCT DEVELOPMENT | $70,867 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $9,192 | CHECK/WIRE |
| EAST ASIA AND THE PACIFIC | INTERNATIONAL DEVELOPMENT | $64,522 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $8,445 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $6,297 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $6,033 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $9,700 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $43,339 | CHECK/WIRE |
| SOUTH ASIA | PRODUCT DEVELOPMENT | $174,900 | CHECK/WIRE |
| EUROPE | OTHER | $10,000 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PRODUCT DEVELOPMENT | $40,059 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $36,192 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PRODUCT DEVELOPMENT | $652,171 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PRODUCT DEVELOPMENT | $445,431 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $6,353 | CHECK/WIRE |
| EAST ASIA AND THE PACIFIC | PRODUCT DEVELOPMENT | $7,800 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $6,600 | CHECK/WIRE |
| SOUTH ASIA | PRODUCT DEVELOPMENT | $21,484 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | OTHER | $25,379 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $46,810 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $24,936 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $23,883 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $25,158 | CHECK/WIRE |
| EAST ASIA AND THE PACIFIC | PUBLIC HEALTH | $801,124 | CHECK/WIRE |
| EUROPE | PRODUCT DEVELOPMENT | $143,666 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $24,061 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $17,076 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $27,096 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $31,999 | CHECK/WIRE |
| EAST ASIA AND THE PACIFIC | PRODUCT DEVELOPMENT | $177,701 | CHECK/WIRE |
| EAST ASIA AND THE PACIFIC | PRODUCT DEVELOPMENT | $38,287 | CHECK/WIRE |
| EUROPE | PUBLIC HEALTH | $20,360 | CHECK/WIRE |
| EUROPE | PRODUCT DEVELOPMENT | $100,758 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $61,767 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $34,321 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $8,301 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $11,604 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $42,203 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $35,440 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $21,653 | CHECK/WIRE |
| SOUTH AMERICA | PUBLIC HEALTH | $13,858 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $16,859 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $9,696 | CHECK/WIRE |
| SOUTH ASIA | PRODUCT DEVELOPMENT | $733,020 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $174,746 | CHECK/WIRE |
| EUROPE | PRODUCT DEVELOPMENT | $4,391,410 | CHECK/WIRE |
| EAST ASIA AND THE PACIFIC | INTERNATIONAL DEVELOPMENT | $58,516 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | OTHER | $30,000 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $5,192 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $38,863 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | OTHER | $47,475 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PRODUCT DEVELOPMENT | $10,000 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | OTHER | $6,000 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $12,497 | CHECK/WIRE |
| EUROPE | PUBLIC HEALTH | $123,594 | CHECK/WIRE |
| SOUTH ASIA | PRODUCT DEVELOPMENT | $24,650 | CHECK/WIRE |
| EAST ASIA AND THE PACIFIC | INTERNATIONAL DEVELOPMENT | $111,707 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $19,619 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $39,439 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PRODUCT DEVELOPMENT | $580,700 | CHECK/WIRE |
| EUROPE | PRODUCT DEVELOPMENT | $1,552,397 | CHECK/WIRE |
| SOUTH ASIA | PRODUCT DEVELOPMENT | $30,260 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $20,827 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PRODUCT DEVELOPMENT | $69,316 | CHECK/WIRE |
| EUROPE | PUBLIC HEALTH | $60,000 | CHECK/WIRE |
| EUROPE | PUBLIC HEALTH | $105,782 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PRODUCT DEVELOPMENT | $323,717 | CHECK/WIRE |
| EUROPE | PRODUCT DEVELOPMENT | $1,019,121 | CHECK/WIRE |
| EUROPE | PUBLIC HEALTH | $504,882 | CHECK/WIRE |
| EUROPE | PRODUCT DEVELOPMENT | $100,000 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PRODUCT DEVELOPMENT | $77,253 | CHECK/WIRE |
| SOUTH AMERICA | PRODUCT DEVELOPMENT | $9,100 | CHECK/WIRE |
| SOUTH ASIA | PRODUCT DEVELOPMENT | $385,099 | CHECK/WIRE |
| EUROPE | PRODUCT DEVELOPMENT | $16,428 | CHECK/WIRE |
| EUROPE | PUBLIC HEALTH | $50,000 | CHECK/WIRE |
| NORTH AMERICA | PUBLIC HEALTH | $88,458 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PRODUCT DEVELOPMENT | $61,698 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $19,391 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $12,331 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $14,189 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $6,378 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $11,830 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $8,335 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $13,240 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $17,851 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $9,824 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $7,574 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $14,761 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $18,285 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $23,344 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $14,457 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $12,895 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $37,438 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PRODUCT DEVELOPMENT | $811,274 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PRODUCT DEVELOPMENT | $233,045 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $24,468 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | OTHER | $5,000 | CHECK/WIRE |
| EUROPE | PRODUCT DEVELOPMENT | $130,000 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $12,125 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $12,180 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $16,882 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $19,029 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $33,967 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PRODUCT DEVELOPMENT | $363,819 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $6,513 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $8,307 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $28,260 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $12,552 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PRODUCT DEVELOPMENT | $178,559 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $6,286 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $16,403 | CHECK/WIRE |
| EUROPE | PRODUCT DEVELOPMENT | $185,570 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $9,575 | CHECK/WIRE |
| SOUTH ASIA | PUBLIC HEALTH | $50,401 | CHECK/WIRE |
| EUROPE | PRODUCT DEVELOPMENT | $221,047 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $30,081 | CHECK/WIRE |
| EUROPE | INTERNATIONAL DEVELOPMENT | $240,463 | CHECK/WIRE |
| EUROPE | PUBLIC HEALTH | $876,521 | CHECK/WIRE |
| EUROPE | PUBLIC HEALTH | $38,706 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $18,774 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $8,860 | CHECK/WIRE |
| SOUTH ASIA | INTERNATIONAL DEVELOPMENT | $267,908 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $20,814 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $12,156 | CHECK/WIRE |
| SOUTH AMERICA | PRODUCT DEVELOPMENT | $255,898 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $7,417 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $9,043 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $15,923 | CHECK/WIRE |
| SOUTH ASIA | PUBLIC HEALTH | $9,177 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $22,231 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $20,741 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $27,073 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $87,377 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $22,516 | CHECK/WIRE |
| EUROPE | PRODUCT DEVELOPMENT | $8,328 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $17,637 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $13,188 | CHECK/WIRE |
| NORTH AMERICA | PUBLIC HEALTH | $41,211 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $115,186 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $15,222 | CHECK/WIRE |
| EAST ASIA AND THE PACIFIC | PRODUCT DEVELOPMENT | $85,000 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $22,546 | CHECK/WIRE |
| SOUTH AMERICA | PUBLIC HEALTH | $48,567 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $8,593 | CHECK/WIRE |
| CENTRAL AMERICA AND THE CARIBBEAN | PUBLIC HEALTH | $50,859 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $8,245 | CHECK/WIRE |
| EUROPE | PRODUCT DEVELOPMENT | $230,430 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $8,055 | CHECK/WIRE |
| SOUTH AMERICA | INTERNATIONAL DEVELOPMENT | $5,880 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PRODUCT DEVELOPMENT | $123,967 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $22,793 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $10,331 | CHECK/WIRE |
| EUROPE | PUBLIC HEALTH | $8,260 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $12,514 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $16,220 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $18,366 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $5,175 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $24,582 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $10,072 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $17,400 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $17,560 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $20,132 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $12,847 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $20,881 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $7,493 | CHECK/WIRE |
| EUROPE | PRODUCT DEVELOPMENT | $877,721 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $6,271 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $14,400 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $23,404 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PRODUCT DEVELOPMENT | $16,386 | CHECK/WIRE |
| EAST ASIA AND THE PACIFIC | INTERNATIONAL DEVELOPMENT | $1,040,941 | CHECK/WIRE |
| SOUTH AMERICA | PUBLIC HEALTH | $50,000 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $8,794 | CHECK/WIRE |
| EUROPE | PRODUCT DEVELOPMENT | $11,059 | CHECK/WIRE |
| EUROPE | PRODUCT DEVELOPMENT | $273,164 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $31,928 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $31,061 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $10,494 | CHECK/WIRE |
| NORTH AMERICA | PUBLIC HEALTH | $26,100 | CHECK/WIRE |
| SOUTH ASIA | PUBLIC HEALTH | $54,000 | CHECK/WIRE |
| SOUTH AMERICA | PUBLIC HEALTH | $5,000 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $16,427 | CHECK/WIRE |
| EAST ASIA AND THE PACIFIC | PRODUCT DEVELOPMENT | $100,000 | CHECK/WIRE |
| EUROPE | PRODUCT DEVELOPMENT | $411,130 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $10,410 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $14,727 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $14,057 | CHECK/WIRE |
| EAST ASIA AND THE PACIFIC | PRODUCT DEVELOPMENT | $5,540 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $5,264 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $9,963 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $7,348 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $7,839 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $5,212 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $8,661 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | OTHER | $25,690 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $42,268 | CHECK/WIRE |
| EUROPE | PRODUCT DEVELOPMENT | $250,000 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $11,635 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $12,001 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $7,776 | CHECK/WIRE |
| SOUTH ASIA | PRODUCT DEVELOPMENT | $320,000 | CHECK/WIRE |
| EUROPE | PRODUCT DEVELOPMENT | $3,300,736 | CHECK/WIRE |
| EUROPE | PUBLIC HEALTH | $2,712 | CHECK/WIRE |
| EUROPE | OTHER | $2,353,409 | CHECK/WIRE |
| EUROPE | PRODUCT DEVELOPMENT | $91,684 | CHECK/WIRE |
| EAST ASIA AND THE PACIFIC | PRODUCT DEVELOPMENT | $54,136 | CHECK/WIRE |
| EAST ASIA AND THE PACIFIC | PRODUCT DEVELOPMENT | $29,972 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $15,350 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $15,184 | CHECK/WIRE |
| EAST ASIA AND THE PACIFIC | PRODUCT DEVELOPMENT | $58,071 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $11,961 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PRODUCT DEVELOPMENT | $9,887 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $30,939 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $8,937 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $25,986 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $14,896 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $8,305 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $12,106 | CHECK/WIRE |
| SOUTH AMERICA | INTERNATIONAL DEVELOPMENT | $5,859 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $23,435 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | OTHER | $25,000 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $290,187 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $11,231 | CHECK/WIRE |
| EUROPE | PRODUCT DEVELOPMENT | $181,236 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $28,048 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $37,549 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $5,376 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $22,634 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PRODUCT DEVELOPMENT | $92,952 | CHECK/WIRE |
| SOUTH ASIA | PRODUCT DEVELOPMENT | $12,781 | CHECK/WIRE |
| SOUTH ASIA | PRODUCT DEVELOPMENT | $42,431 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $12,723 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PRODUCT DEVELOPMENT | $11,656 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $7,548 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $15,422 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $8,176 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $21,923 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | OTHER | $5,000 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $147,061 | CHECK/WIRE |
| EUROPE | PRODUCT DEVELOPMENT | $280,092 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $257,347 | CHECK/WIRE |
| EUROPE | PRODUCT DEVELOPMENT | $56,743 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PRODUCT DEVELOPMENT | $201,868 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $219,959 | CHECK/WIRE |
| EUROPE | PRODUCT DEVELOPMENT | $841,382 | CHECK/WIRE |
| EUROPE | PRODUCT DEVELOPMENT | $34,641 | CHECK/WIRE |
| EUROPE | PRODUCT DEVELOPMENT | $1,602,157 | CHECK/WIRE |
| EUROPE | PUBLIC HEALTH | $52,208 | CHECK/WIRE |
| NORTH AMERICA | PRODUCT DEVELOPMENT | $26,450 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $29,942 | CHECK/WIRE |
| EAST ASIA AND THE PACIFIC | PRODUCT DEVELOPMENT | $24,000 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $9,686 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $11,631 | CHECK/WIRE |
| EUROPE | PRODUCT DEVELOPMENT | $290,300 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $35,147 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $6,764 | CHECK/WIRE |
| EAST ASIA AND THE PACIFIC | PRODUCT DEVELOPMENT | $302,872 | CHECK/WIRE |
| EAST ASIA AND THE PACIFIC | PUBLIC HEALTH | $75,000 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $20,993 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $19,171 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $18,993 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $13,007 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $10,231 | CHECK/WIRE |
| SOUTH AMERICA | PUBLIC HEALTH | $10,524 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | OTHER | $5,944 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PRODUCT DEVELOPMENT | $59,745 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PRODUCT DEVELOPMENT | $292,417 | CHECK/WIRE |
| EUROPE | INTERNATIONAL DEVELOPMENT | $295,000 | CHECK/WIRE |
| EUROPE | PRODUCT DEVELOPMENT | $917,344 | CHECK/WIRE |
| EUROPE | PUBLIC HEALTH | $42,039 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $22,984 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $12,987 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $10,628 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | INTERNATIONAL DEVELOPMENT | $58,781 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $21,949 | CHECK/WIRE |
| SUB-SAHARAN AFRICA | PUBLIC HEALTH | $167,409 | CHECK/WIRE |
| EAST ASIA AND THE PACIFIC | INTERNATIONAL DEVELOPMENT | -$179 | CHECK/WIRE |
| EAST ASIA AND THE PACIFIC | INTERNATIONAL DEVELOPMENT | -$12,850 | CHECK/WIRE |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total501c3 Org | 274 | Total501c3OrgCnt |
| Total Other Org | 50 | TotalOtherOrgCnt |
| Transfer To Foreign Corp | Yes (1) | TransferToForeignCorpInd |
| Interest In Foreign Trust | 0 | InterestInForeignTrustInd |
| Foreign Corp Ownership | 0 | ForeignCorpOwnershipInd |
| Passive Foreign Investmest Co | 0 | PassiveForeignInvestmestCoInd |
| Foreign Partnership | 0 | ForeignPartnershipInd |
| Boycott Countries | 0 | BoycottCountriesInd |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART I, LINE 2: | FormAndLineReferenceDesc |
| Explanation | SUBRECIPIENTS MUST SUBMIT PROGRESS REPORTS THAT ARE REVIEWED BY RESPONSIBLE PATH PROGRAM MANAGERS AND PROGRAM ADMINISTRATORS TO ENSURE THAT PROGRAM GOALS ARE ATTAINED IN ACCORDANCE WITH AGREEMENT REQUIREMENTS. THE RESPONSIBLE PROGRAM MANAGERS AND PROGRAM ADMINISTRATORS CONTACT SUBRECIPIENTS WITH QUESTIONS OR FOLLOW UP ON ANY AREA OF CONCERN. IN SOME CASES, SUBAWARD TERMS MAY REQUIRE SPECIFIED DELIVERABLES IN ADDITION TO, OR IN LIEU OF, TECHNICAL REPORTS. IN ADDITION, DISCRETIONARY ON-SITE VISITS ARE CONDUCTED TO EVALUATE BOTH COMPLIANCE WITH THE SCIENTIFIC OBJECTIVES OF THE PROJECT AND THE APPROPRIATENESS OF THE SUBRECIPIENT'S ADMINISTRATIVE SYSTEMS AND PROCESSES. PATH ALSO USES CROSS-PROGRAM INDICATORS TO TRACK OVERALL ORGANIZATIONAL PERFORMANCE AND LINK OUR WORK AND THE WORK OF SUBRECIPIENTS TO SPECIFIC IMPROVEMENTS IN HEALTH-RELATED OUTCOMES. MONITORING THIS SET OF INDICATORS HELPS PATH SET FUTURE BENCHMARKS AND ADOPT BEST PRACTICES THAT IMPROVE PROGRAMMATIC EFFECTIVENESS OVER TIME. | ExplanationTxt |
Schedule G IRS990ScheduleG
Fundraising Event Information FundraisingEventInformationGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Event1 | GOLF BENEFIT | Event1Nm |
| Gross Receipts Event1 | $177,120 | GrossReceiptsEvent1Amt |
| Charitable Contri Event1 | $35,220 | CharitableContriEvent1Amt |
| Gross Revenue Event1 | $141,900 | GrossRevenueEvent1Amt |
| Non Cash Prizes Event1 | $38,218 | NonCashPrizesEvent1Amt |
| Rent Facility Costs Event1 | $54,379 | RentFacilityCostsEvent1Amt |
| Entertainment Event1 | $2,786 | EntertainmentEvent1Amt |
| Other Direct Expenses Event1 | $9,876 | OtherDirectExpensesEvent1Amt |
| Gross Receipts Total | $177,120 | GrossReceiptsTotalAmt |
| Charitable Contributions Tot | $35,220 | CharitableContributionsTotAmt |
| Gross Revenue Total Events | $141,900 | GrossRevenueTotalEventsAmt |
| Non Cash Prizes Total Events | $38,218 | NonCashPrizesTotalEventsAmt |
| Rent Fclty Costs Total Events | $54,379 | RentFcltyCostsTotalEventsAmt |
| Entertainment Total Events | $2,786 | EntertainmentTotalEventsAmt |
| Oth Direct Expnss Total Events | $9,876 | OthDirectExpnssTotalEventsAmt |
| Direct Expense Summary Events | $105,259 | DirectExpenseSummaryEventsAmt |
| Net Income Summary | $36,641 | NetIncomeSummaryAmt |
Schedule I IRS990ScheduleI
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Records Maintained | Yes (1) | GrantRecordsMaintainedInd |
Recipient Table RecipientTable (89 entries)
| Address Line1USAddress/AddressLine1Txt | CityUSAddress/CityNm | State AbbreviationUSAddress/StateAbbreviationCd | ZIPUSAddress/ZIPCd | Recipient EINRecipientEIN | IRC SectionIRCSectionDesc | Cash GrantCashGrantAmt | Purpose Of GrantPurposeOfGrantTxt | Address Line2USAddress/AddressLine2Txt |
|---|---|---|---|---|---|---|---|---|
| ACCELOVANCE INC | ||||||||
| 2275 RESEARCH BOULEVARD SUITE 700 | ROCKVILLE | MD | 20850 | 200956757 | N/A | $744,175 | PRODUCT DEVELOPMENT | |
| ADVANCED BIOSCIENCE LABORATORIES INC | ||||||||
| 9800 MEDICAL CENTER DRIVE BUILDING | ROCKVILLE | MD | 20850 | 621242262 | N/A | $178,400 | PRODUCT DEVELOPMENT | D |
| AKROS INC - RESEARCH ANALYTICS | ||||||||
| 3350 LAZERA RANCH ROAD | CHEYENNE | WY | 82007 | 263668995 | N/A | $309,411 | INTERNATIONAL DEVELOPMENT | |
| APPLIED STRATEGIES CONSULTING LLC | ||||||||
| 951 MARINERS ISLAND BLVD SUITE 400 | SAN MATEO | CA | 94404 | 331026972 | N/A | $25,876 | PUBLIC HEALTH | |
| BASIC HEALTH INTERNATIONAL INC | ||||||||
| THE MOUNT SINAI MEDICAL CENTER ONE | NEW YORK | NY | 10029 | 203408717 | 501(C)(3) | $263,348 | PUBLIC HEALTH | GUSTAV L LEVY PLACE PO BOX 1170 |
| BOSTON UNIVERSITY | ||||||||
| ONE SILBER WAY | BOSTON | MA | 02215 | 042103547 | 501(C)(3) | $178,517 | PUBLIC HEALTH | |
| BOSTON UNIVERSITY | ||||||||
| ONE SILBER WAY | BOSTON | MA | 02215 | 042103547 | 501(C)(3) | $26,887 | PRODUCT DEVELOPMENT | |
| BROADREACH HEALTHCARE LLC | ||||||||
| 1655 NORTH FORT MYER DR SUITE 700 | ARLINGTON | VA | 22209 | 861052728 | N/A | $309,328 | INTERNATIONAL DEVELOPMENT | |
| CASCADE DESIGNS INC | ||||||||
| 4000 FIRST AVENUE SOUTH | SEATTLE | WA | 98134 | 910969695 | N/A | $9,624 | PRODUCT DEVELOPMENT | |
| CDC FOUNDATION | ||||||||
| CDC FOUNDATION 55 PARK PLACE NE | ATLANTA | GA | 30303 | 582106707 | 501(C)(3) | $449,939 | PRODUCT DEVELOPMENT | SUITE 400 |
| CHILDFUND INTERNATIONAL | ||||||||
| 2821 EMERYWOOD PARKWAY | RICHMOND | VA | 23294 | 540536100 | 501(C)(3) | $96,066 | PUBLIC HEALTH | |
| CHRISTIAN CONNECTIONS FOR INTERNATIONAL HEALTH | ||||||||
| 1329 SHEPARD DRIVE SUITE 7 | STERLING | VA | 20164 | 541932761 | 501(C)(3) | $79,905 | PUBLIC HEALTH | |
| CONRAD | ||||||||
| EASTERN VIRGINIA MEDICAL SCHOOL | ARLINGTON | VA | 22209 | 237053028 | 501(C)(3) | $250,000 | PRODUCT DEVELOPMENT | 1611 N KENT ST SUITE 806 |
| ECHODITTO INC | ||||||||
| ONE DAVIS SQUARE STE 302 | SOMERVILLE | MA | 02144 | 200134367 | N/A | $81,260 | PUBLIC HEALTH | |
| ELIZABETH GLASER PEDIATRIC AIDS FOUNDATION | ||||||||
| 1140 CONNECTICUT AVENUE NW | WASHINGTON | DC | 20036 | 954191698 | 501(C)(3) | $3,138,967 | INTERNATIONAL DEVELOPMENT | |
| EMORY UNIVERSITY | ||||||||
| 201 DOWMAN DRIVE | ATLANTA | GA | 30322 | 580566256 | 501(C)(3) | $364,418 | PUBLIC HEALTH | |
| EMORY UNIVERSITY | ||||||||
| 201 DOWMAN DRIVE | ATLANTA | GA | 30322 | 580566256 | 501(C)(3) | $49,135 | PRODUCT DEVELOPMENT | |
| EXPRESSION ANALYSIS INC | ||||||||
| 4326 S ALSTON AVE 101 | DURHAM | NC | 27713 | 522340631 | N/A | $25,000 | PRODUCT DEVELOPMENT | |
| FAMILY CARE INTERNATIONAL INC | ||||||||
| 45 BROADWAY SUITE 320 | NEW YORK | NY | 10006 | 237413005 | 501(C)(3) | $134,908 | PUBLIC HEALTH | |
| FHI 360 | ||||||||
| FHI 360 HEADQUARTERS 359 BLACKWELL | DURHAM | NC | 27701 | 237413005 | 501(C)(3) | $743,953 | PUBLIC HEALTH | ST SUITE 200 |
| FINA BIOSOLUTIONS LLC | ||||||||
| 9430 KEY WEST AVE SUITE 200 | ROCKVILLE | MD | 20850 | 205448275 | N/A | $53,568 | PRODUCT DEVELOPMENT | |
| FINANCING FOR DEVELOPMENT | ||||||||
| 1800 MASSACHUSETTS AVENUE SUITE 400 | WASHINGTON | DC | 20036 | 680683026 | 501(C)(3) | $313,956 | PUBLIC HEALTH | 400 |
| FOOD & DRUG ADMINISTRATION | ||||||||
| 10903 NEW HAMPSHIRE AVENUE | SILVER SPRING | MD | 20993 | 530196965 | GOVERNMENT | $407,170 | PRODUCT DEVELOPMENT | |
| FRAUNHOFER USA CENTER FOR MOLECULAR BIOTECHNOLOGY | ||||||||
| 9 INNOVATION WAY SUITE 200 | NEWARK | DE | 19711 | 383203030 | 501(C)(3) | $230,937 | PRODUCT DEVELOPMENT | |
| FRED HUTCHINSON CANCER RESEARCH CENTER | ||||||||
| PO BOX 19024 | SEATTLE | WA | 98109 | 237156071 | 501(C)(3) | $142,779 | PRODUCT DEVELOPMENT | |
| GEORGE W BUSH INSTITUTE | ||||||||
| 2943 SMU BLVD | DALLAS | TX | 75205 | 204119317 | 501(C)(3) | $25,000 | PUBLIC HEALTH | |
| GLOBAL HEALTH INSIGHTS LLC | ||||||||
| 3 PETER COOPER ROAD APT MC | NEW YORK | NY | 10010 | 263809493 | N/A | $69,534 | PUBLIC HEALTH | |
| GMMB INC | ||||||||
| 1200 WESTLAKE AVENUE N SUITE 1005 | SEATTLE | WA | 98109 | 521305983 | N/A | $95,463 | PUBLIC HEALTH | |
| GREENEWORKS GLOBAL LLC | ||||||||
| 3733 WARREN STREET NW | WASHINGTON | DC | 20016 | 800672849 | N/A | $31,000 | PUBLIC HEALTH | |
| HARVARD UNIVERSITY SCHOOL OF PUBLIC HEALTH | ||||||||
| 1033 MASSACHUSETTS AVE STE 3 | CAMBRIDGE | MA | 02138 | 042103580 | 501(C)(3) | -$10,450 | PUBLIC HEALTH | |
| IBIS REPRODUCTIVE HEALTH | ||||||||
| 17 DUNSTER STREET SUITE 201 | CAMBRIDGE | MA | 02138 | 030382773 | 501(C)(3) | $105,612 | PUBLIC HEALTH | |
| INITIATIVES INC | ||||||||
| 264 BEACON STREET | BOSTON | MA | 02116 | 042961350 | N/A | $113,017 | INTERNATIONAL DEVELOPMENT | |
| INOVIO PHARMACEUTICALS | ||||||||
| 1787 SENTRY PARKWAY WEST BLDG 18- | BLUE BELL | PA | 19422 | 330969592 | N/A | $50,000 | PRODUCT DEVELOPMENT | SUITE 400 |
| INTERNATIONAL AIDS VACCINE INITIATIVE | ||||||||
| 110 WILLIAM ST 27TH FLOOR | NEW YORK | NY | 10038 | 133870223 | 501(C)(3) | $192,630 | PRODUCT DEVELOPMENT | |
| INTERNATIONAL PLANNED PARENTHOOD FEDERATION WESTERN HEMISPHERE REGION | ||||||||
| 125 MAIDEN LANE 9TH FLOOR | NEW YORK | NY | 10038 | 131845455 | 501(C)(3) | $39,522 | PUBLIC HEALTH | |
| INTRAHEALTH INTERNATIONAL | ||||||||
| 6340 QUADRANGLE DRIVE SUITE 200 | CHAPEL HILL | NC | 27514 | 550825466 | 501(C)(3) | $147,908 | PUBLIC HEALTH | |
| JHPIEGO | ||||||||
| 1615 THAMES STREET | BALTIMORE | MD | 21231 | 237424444 | 501(C)(3) | $1,702,770 | INTERNATIONAL DEVELOPMENT | |
| JHPIEGO | ||||||||
| 1615 THAMES STREET | BALTIMORE | MD | 21231 | 237424444 | 501(C)(3) | $99,998 | PUBLIC HEALTH | |
| JHU BLOOMBERG SCHOOL OF PUBLIC HEALTH | ||||||||
| 615 N WOLFE STREET | BALTIMORE | MD | 21205 | 131687001 | 501(C)(3) | $482,772 | PRODUCT DEVELOPMENT | |
| JOHN SNOW INC | ||||||||
| 44 FARNSWORTH STREET | BOSTON | MA | 02210 | 042578580 | N/A | $204,467 | PRODUCT DEVELOPMENT | |
| JOHN SNOW INC | ||||||||
| 44 FARNSWORTH STREET | BOSTON | MA | 02210 | 042578580 | N/A | $7,600 | PUBLIC HEALTH | |
| JOHNS HOPKINS UNIVERSITY | ||||||||
| OFFICE OF RESEARCH ADMINISTRATION | BALTIMORE | MD | 21205 | 131687001 | 501(C)(3) | $494,201 | PRODUCT DEVELOPMENT | 615 N WOLFE STREET W1100 |
| JSIR&T | ||||||||
| 1616 NORTH FORT MYER DRIVE 11TH | ARLINGTON | VA | 22209 | 042578580 | N/A | $77,418 | PUBLIC HEALTH | FLOOR |
| KYBELE INC | ||||||||
| 3524 YADKINVILLE ROAD 124 | WINSTON SALEM | NC | 27106 | 900759003 | 501(C)(3) | $408,273 | PUBLIC HEALTH | |
| LOYOLA UNIVERSITY CHICAGO | ||||||||
| 6339 N SHERIDAN ROAD | CHICAGO | IL | 60660 | 361408475 | 501(C)(3) | $149,693 | PRODUCT DEVELOPMENT | |
| MEDICAL CARE DEVELOPMENT INC | ||||||||
| 8401 COLESVILLE ROAD SUITE 425 | SILVER SPRING | MD | 20910 | 016022787 | 501(C)(3) | $2,672,982 | PUBLIC HEALTH | |
| NEW YORK UNIVERSITY | ||||||||
| 726 BROADWAY FLOOR 10 ROOM 1024 | NEW YORK | NY | 10003 | 135562308 | 501(C)(3) | $81,695 | PRODUCT DEVELOPMENT | |
| NIH NATIONAL INSTITUTE OF ALLERGY AND INFECTIOUS DISEASES | ||||||||
| 6610 ROCKLEDGE DRIVE MSC 6612 | BETHESDA | MD | 20892 | 520858115 | GOVERNMENT | $1,443,022 | PRODUCT DEVELOPMENT | |
| NORTIS INC | ||||||||
| C4C NEW VENTURE FACILITY 4000 MASON | SEATTLE | WA | 98195 | 680649212 | 501(C)(3) | $60,924 | PRODUCT DEVELOPMENT | RD ROOM 304 FLUKE HALL PO BOX 35214 |
| PAN AMERICAN HEALTH ORGANIZATION | ||||||||
| 1889 F STREET SUITE 312 | WASHINGTON | DC | 20006 | 237072046 | 501(C)(3) | -$62,251 | PRODUCT DEVELOPMENT | |
| PATH DRUG SOLUTIONS | ||||||||
| 2201 WESTLAKE AVE SUITE 200 | SEATTLE | WA | 98121 | 943384500 | 501(C)(3) | $798,172 | GENERAL SUPPORT | |
| PATHFINDER INTERNATIONAL | ||||||||
| NINE GALEN STREET SUITE 217 | WATERTOWN | MA | 02472 | 530235320 | 501(C)(3) | $442,732 | PUBLIC HEALTH | |
| POPULATION ACTION INTERNATIONAL | ||||||||
| 1300 19TH STREET NW | WASHINGTON | DC | 20036 | 520812075 | 501(C)(3) | $12,409 | OTHER | |
| POPULATION COUNCIL | ||||||||
| ONE DAG HAMMARSKJOLD PLAZA 3RD | NEW YORK | NY | 10017 | 131687001 | 501(C)(3) | $1,151,403 | PUBLIC HEALTH | FLOOR |
| POPULATION SERVICES INTERNATIONAL | ||||||||
| 1120 19TH STREET NW SUITE 600 | WASHINGTON | DC | 20036 | 560942853 | 501(C)(3) | $624,285 | PUBLIC HEALTH | |
| POPULATION SERVICES INTERNATIONAL | ||||||||
| 1120 19TH STREET NW SUITE 600 | WASHINGTON | DC | 20036 | 560942853 | 501(C)(3) | $107,241 | PRODUCT DEVELOPMENT | |
| PUBLIC HEALTH INSTITUTE | ||||||||
| 555 12TH STREET 10TH FLOOR | OAKLAND | CA | 94607 | 941646278 | 501(C)(3) | $423,465 | PRODUCT DEVELOPMENT | |
| SABIN VACCINE INSTITUTE | ||||||||
| 2000 PENNSYLVANIA AVENUE SUITE 7100 | WASHINGTON | DC | 20006 | 061389829 | 501(C)(3) | $100,000 | PRODUCT DEVELOPMENT | 7100 |
| SANARIA INC | ||||||||
| 9800 MEDICAL CENTER DRIVE SUITE | ROCKVILLE | MD | 20850 | 562354362 | N/A | $979,589 | PRODUCT DEVELOPMENT | A209 |
| SAVE THE CHILDREN | ||||||||
| 501 KINGS HIGHWAY | FAIRFIELD | CT | 06825 | 060726487 | 501(C)(3) | $156,007 | PUBLIC HEALTH | |
| SAVE THE CHILDREN | ||||||||
| 501 KINGS HIGHWAY | FAIRFIELD | CT | 06825 | 060726487 | 501(C)(3) | $18,000 | PRODUCT DEVELOPMENT | |
| SEATTLE BIOMEDICAL RESEARCH INSTITUTE | ||||||||
| 307 WESTLAKE AVE N SUITE 500 | SEATTLE | WA | 98109 | 910961784 | 501(C)(3) | $1,464,598 | PRODUCT DEVELOPMENT | |
| SHIFT LABS INC | ||||||||
| 1752 NW MARKET ST 211 | SEATTLE | WA | 98107 | 454541971 | N/A | $8,000 | PUBLIC HEALTH | |
| TULANE EDUCATIONAL FUND THE ADMINISTRATORS OF THE | ||||||||
| 1430 TULANE AVENUE TB-32 | NEW ORLEANS | LA | 70112 | 720423889 | 501(C)(3) | $21,670 | PRODUCT DEVELOPMENT | |
| TULANE UNIVERSITY SCHOOL OF PUBLIC HEALTH AND TROPICAL MEDICINE | ||||||||
| 1440 CANAL ST | NEW ORLEANS | LA | 70112 | 720423889 | 501(C)(3) | $170,975 | PUBLIC HEALTH | |
| TULANE UNIVERSITY OFFICE OF GRANTS AND CONTRACTS ACCOUNTING | ||||||||
| 800 EAST COMMERCE ROAD SUITE 203 | HARAHAN | LA | 70123 | 720423889 | 501(C)(3) | $10,778 | INTERNATIONAL DEVELOPMENT | |
| UNITED NATIONS FUND FOR POPULATION ACTIVITIES | ||||||||
| 220 EAST 42ND STREET | NEW YORK | NY | 10017 | GOVERNMENT | $124,517 | PUBLIC HEALTH | ||
| UNITED STATES NAVAL MEDICAL RESEARCH CENTER | ||||||||
| 503 ROBERT GRANT AVE | SILVER SPRING | MD | 20910 | 470100048 | GOVERNMENT | $647,619 | PRODUCT DEVELOPMENT | |
| UNITED STATES PHARMACOPEIAL CONVENTION | ||||||||
| USP HEADQUARTERS 12601 TWIN BROOK | ROCKVILLE | MD | 20852 | 131656692 | 501(C)(3) | $45,567 | PRODUCT DEVELOPMENT | PARKWAY |
| UNIVERSITY OF ALABAMA AT BIRMINGHAM | ||||||||
| 701 20TH STREET SOUTH AB 1170 | BIRMINGHAM | AL | 35294 | 636005396 | 501(C)(3) | $200,000 | PRODUCT DEVELOPMENT | |
| UNIVERSITY OF FLORIDA | ||||||||
| 219 GRINTER HALL PO BOX 115500 | GAINESVILLE | FL | 32611 | 596002052 | 501(C)(3) | $18,566 | PRODUCT DEVELOPMENT | |
| UNIVERSITY OF MARYLAND BALTIMORE | ||||||||
| PO BOX 41428 | BALTIMORE | MD | 21203 | 526002033 | 501(C)(3) | $453,519 | PRODUCT DEVELOPMENT | |
| UNIVERSITY OF MIAMI | ||||||||
| 1320 SOUTH DIXIE HIGHWAY GABLES ONE | CORAL GABLES | FL | 33146 | 590624458 | 501(C)(3) | $223,728 | PRODUCT DEVELOPMENT | TOWER SUITE 650 |
| UNIVERSITY OF NORTH CAROLINA | ||||||||
| 720 MARTIN LUTHER KING JR BLVD | CHAPEL HILL | NC | 27599 | 566001393 | 501(C)(3) | $305,850 | PRODUCT DEVELOPMENT | SUITE |
| UNIVERSITY OF SOUTH FLORIDA | ||||||||
| 4202 E FOWLER AVE | TAMPA | FL | 33620 | 593102112 | 501(C)(3) | $37,888 | PRODUCT DEVELOPMENT | |
| UNIVERSITY OF VERMONT AND STATE AGRICULTURAL COLLEGE | ||||||||
| 85 SOUTH PROSPECT STREET WATERMAN | BURLINGTON | VT | 05405 | 030179440 | 501(C)(3) | $47,000 | PRODUCT DEVELOPMENT | 217 |
| UNIVERSITY OF WASHINGTON | ||||||||
| 4333 BROOKLYN AVE NE BOX 359472 | SEATTLE | WA | 98195 | 916001537 | 501(C)(3) | $349,038 | PRODUCT DEVELOPMENT | |
| UNIVERSITY OF WASHINGTON | ||||||||
| 4333 BROOKLYN AVE NE BOX 359472 | SEATTLE | WA | 98195 | 916001537 | 501(C)(3) | $5,000 | OTHER | |
| UNIVERSITY OF WASHINGTON HARBORVIEW MEDICAL CENTER INFECTIOUS DISEASES RES | ||||||||
| HARBORVIEW MEDICAL CENTER 325 9TH | SEATTLE | WA | 98104 | 916001537 | 501(C)(3) | $11,684 | PRODUCT DEVELOPMENT | AVE BOX 359932 |
| VENTURE STRATEGIES INNOVATIONS | ||||||||
| 19200 VON KARMAN AVENUE SUITE 400 | IRVINE | CA | 92612 | 262813021 | 501(C)(3) | $60,057 | PRODUCT DEVELOPMENT | |
| VILLAGEREACH | ||||||||
| 2900 EASTLAKE AVE E STE 230 | SEATTLE | WA | 98102 | 912082484 | 501(C)(3) | $22,295 | PRODUCT DEVELOPMENT | |
| WALTER REED ARMY INSTITUTE OF RESEARCH | ||||||||
| 503 ROBERT GRANT DRIVE | SILVER SPRING | MD | 20910 | 520664528 | GOVERNMENT | $2,128,235 | PRODUCT DEVELOPMENT | |
| WIDENET CONSULTING GROUP | ||||||||
| 2910 1ST AVENUE S SUITE 200 | SEATTLE | WA | 98134 | 264198815 | N/A | $333,308 | PUBLIC HEALTH | |
| WIDENET CONSULTING GROUP | ||||||||
| 2910 1ST AVENUE S SUITE 200 | SEATTLE | WA | 98134 | 264198815 | N/A | $30,173 | OTHER | |
| WOMEN DELIVER | ||||||||
| 588 BROADWAY SUITE 5033 | NEW YORK | NY | 10012 | 264462256 | 501(C)(3) | $90,000 | OTHER | |
| WORKTANK ENTERPRISES LLC | ||||||||
| 400 EAST PINE STREET SUITE 301 | SEATTLE | WA | 98122 | 912089916 | N/A | $88,476 | PUBLIC HEALTH | |
| WORLD VISION DC | ||||||||
| 300 I ST NE | WASHINGTON DC | DC | 20002 | 951922279 | 501(C)(3) | $1,631,107 | INTERNATIONAL DEVELOPMENT | |
| WORLD VISION DC | ||||||||
| 300 I ST NE | WASHINGTON DC | DC | 20002 | 951922279 | 501(C)(3) | $25,000 | OTHER | |
| YALE UNIVERSITY | ||||||||
| GRANTS AND CONTRACT FINANCIAL | NEW HAVEN | CT | 06508 | 060646973 | 501(C)(3) | $92,081 | PRODUCT DEVELOPMENT | ADMINISTRATION PO BOX 1873 |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Total501c3 Org | 56 | Total501c3OrgCnt |
| Total Other Org | 24 | TotalOtherOrgCnt |
Grants Other Asst To Indiv In US GrantsOtherAsstToIndivInUSGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Grant Type | PUBLIC HEALTH | GrantTypeTxt |
| Recipient | 1 | RecipientCnt |
| Cash Grant | $250,504 | CashGrantAmt |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART I, LINE 2: | FormAndLineReferenceDesc |
| Explanation | SUBRECIPIENTS MUST SUBMIT PROGRESS REPORTS THAT ARE REVIEWED BY RESPONSIBLE PATH PROGRAM MANAGERS AND PROGRAM ADMINISTRATORS TO ENSURE THAT PROGRAM GOALS ARE ATTAINED IN ACCORDANCE WITH AGREEMENT REQUIREMENTS. THE RESPONSIBLE PROGRAM MANAGERS AND PROGRAM ADMINISTRATORS CONTACT SUBRECIPIENTS WITH QUESTIONS OR FOLLOW UP ON ANY AREA OF CONCERN. IN SOME CASES, SUBAWARD TERMS MAY REQUIRE SPECIFIED DELIVERABLES IN ADDITION TO, OR IN LIEU OF, TECHNICAL REPORTS. IN ADDITION, DISCRETIONARY ON-SITE VISITS ARE CONDUCTED TO EVALUATE BOTH COMPLIANCE WITH THE SCIENTIFIC OBJECTIVES OF THE PROJECT AND THE APPROPRIATENESS OF THE SUBRECIPIENT'S ADMINISTRATIVE SYSTEMS AND PROCESSES. PATH ALSO USES CROSS-PROGRAM INDICATORS TO TRACK OVERALL ORGANIZATIONAL PERFORMANCE AND LINK OUR WORK AND THE WORK OF SUBRECIPIENTS TO SPECIFIC IMPROVEMENTS IN HEALTH-RELATED OUTCOMES. MONITORING THIS SET OF INDICATORS HELPS PATH SET FUTURE BENCHMARKS AND ADOPT BEST PRACTICES THAT IMPROVE PROGRAMMATIC EFFECTIVENESS OVER TIME. | ExplanationTxt |
Schedule J IRS990ScheduleJ
| Field | Value | IRS element (for citing) |
|---|---|---|
| Idemnification Gross Up Pmts | Yes (X) | IdemnificationGrossUpPmtsInd |
| Housing Allowance Or Residence | Yes (X) | HousingAllowanceOrResidenceInd |
| Written Policy Ref T And E Expnss | Yes (1) | WrittenPolicyRefTAndEExpnssInd |
| Substantiation Required | Yes (1) | SubstantiationRequiredInd |
| Compensation Committee | Yes (X) | CompensationCommitteeInd |
| Independent Consultant | Yes (X) | IndependentConsultantInd |
| Compensation Survey | Yes (X) | CompensationSurveyInd |
| Board Or Committee Approval | Yes (X) | BoardOrCommitteeApprovalInd |
| Severance Payment | 0 | SeverancePaymentInd |
| Supplemental Nonqual Rtr Plan | 0 | SupplementalNonqualRtrPlanInd |
| Equity Based Comp Arrngm | 0 | EquityBasedCompArrngmInd |
| Comp Based On Revenue Of Flng Org | 0 | CompBasedOnRevenueOfFlngOrgInd |
| Comp Bsd On Rev Related Orgs | 0 | CompBsdOnRevRelatedOrgsInd |
| Comp Bsd Net Earns Flng Org | 0 | CompBsdNetEarnsFlngOrgInd |
| Comp Bsd Net Earns Rltd Orgs | 0 | CompBsdNetEarnsRltdOrgsInd |
| Any Non Fixed Payments | Yes (1) | AnyNonFixedPaymentsInd |
| Initial Contract Exception | 0 | InitialContractExceptionInd |
Rltd Org Officer Trst Key Empl RltdOrgOfficerTrstKeyEmplGrp (20 entries)
| TitleTitleTxt | Base Compensation Filing OrgBaseCompensationFilingOrgAmt | Compensation Based On Rltd OrgsCompensationBasedOnRltdOrgsAmt | Bonus Filing OrganizationBonusFilingOrganizationAmount | Bonus Related OrganizationsBonusRelatedOrganizationsAmt | Other Compensation Filing OrgOtherCompensationFilingOrgAmt | Other Compensation Rltd OrgsOtherCompensationRltdOrgsAmt | Deferred Compensation Flng OrgDeferredCompensationFlngOrgAmt | Deferred Comp Rltd OrgsDeferredCompRltdOrgsAmt | Nontaxable Benefits Filing OrgNontaxableBenefitsFilingOrgAmt | Nontaxable Benefits Rltd OrgsNontaxableBenefitsRltdOrgsAmt | Total Compensation Filing OrgTotalCompensationFilingOrgAmt | Total Compensation Rltd OrgsTotalCompensationRltdOrgsAmt | Comp Report Prior990 Filing OrgCompReportPrior990FilingOrgAmt | Comp Report Prior990 Rltd OrgsCompReportPrior990RltdOrgsAmt |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| STEVEN B DAVIS | ||||||||||||||
| PRESIDENT AND CEO | $421,692 | $0 | $147,592 | $0 | $700 | $0 | $31,000 | $0 | $12,512 | $0 | $613,496 | $0 | $0 | $0 |
| MICHAEL B KOLLINS | ||||||||||||||
| CHIEF OPERATING OFFICER | $275,004 | $0 | $0 | $0 | $770 | $0 | $28,133 | $0 | $12,512 | $0 | $316,419 | $0 | $0 | $0 |
| OLIVIA POLIUS | ||||||||||||||
| CHIEF FINANCIAL OFFICER | $255,000 | $0 | $0 | $0 | $770 | $0 | $30,281 | $0 | $9,363 | $0 | $295,414 | $0 | $0 | $0 |
| DAVID C KASLOW | ||||||||||||||
| VP, PRODUCT DEVELOPMENT | $377,000 | $0 | $0 | $0 | $1,301 | $0 | $28,920 | $0 | $12,512 | $0 | $419,733 | $0 | $0 | $0 |
| JOHN W BOSLEGO | ||||||||||||||
| GLOBAL PROG. LDR II (UNTIL 12/2/14) | $328,552 | $0 | $0 | $0 | $0 | $0 | $31,000 | $0 | $9,363 | $0 | $368,915 | $0 | $0 | $0 |
| AMIE E BATSON | ||||||||||||||
| CHIEF STRATEGY OFFICER | $275,004 | $0 | $0 | $0 | $225 | $0 | $31,000 | $0 | $1,472 | $0 | $307,701 | $0 | $0 | $0 |
| RIKKA E TRANGSRUD | ||||||||||||||
| COUNTRY PROGRAM LEADER II | $176,241 | $0 | $0 | $0 | $96,141 | $0 | $19,696 | $0 | $11,558 | $0 | $303,636 | $0 | $0 | $0 |
| ASHLEY J BIRKETT | ||||||||||||||
| GLOBAL PROGRAM LEADER I | $270,783 | $0 | $0 | $0 | $225 | $0 | $13,712 | $0 | $12,512 | $0 | $297,232 | $0 | $0 | $0 |
| KATHLEEN M NEUZIL | ||||||||||||||
| GLOBAL PROGRAM LEADER I | $230,089 | $0 | $25,000 | $0 | $75 | $0 | $26,576 | $0 | $9,344 | $0 | $291,084 | $0 | $0 | $0 |
| DANIEL LASTER | ||||||||||||||
| GENERAL COUNSEL | $250,008 | $0 | $0 | $0 | $840 | $0 | $26,668 | $0 | $12,512 | $0 | $290,028 | $0 | $0 | $0 |
| ANURAG PRABHAKAR MAIRAL | ||||||||||||||
| GLOBAL PROGRAM LEADER I | $236,916 | $0 | $0 | $0 | $75 | $0 | $26,061 | $0 | $12,464 | $0 | $275,516 | $0 | $0 | $0 |
| KATHRYN A O'DRISCOLL | ||||||||||||||
| CHIEF H.R. OFFICER | $223,295 | $0 | $0 | $0 | $630 | $0 | $25,295 | $0 | $12,439 | $0 | $261,659 | $0 | $0 | $0 |
| AYORINDE ALBERT AJAYI | ||||||||||||||
| VP, INTL. DEV. (UNTIL 9/10/14) | $220,691 | $0 | $0 | $0 | $2,000 | $0 | $25,501 | $0 | $5,221 | $0 | $253,413 | $0 | $0 | $0 |
| JANE E HUTCHINGS | ||||||||||||||
| GLOBAL PROGRAM LEADER I | $217,735 | $0 | $0 | $0 | $0 | $0 | $26,128 | $0 | $12,441 | $0 | $256,304 | $0 | $0 | $0 |
| CARLOS CLINTON CAMPBELL | ||||||||||||||
| GLOBAL PROGRAM LEADER I | $187,648 | $0 | $0 | $0 | $18,842 | $0 | $21,457 | $0 | $1,205 | $0 | $229,152 | $0 | $0 | $0 |
| JOHN SKIBIAK | ||||||||||||||
| ASSOCIATE DIRECTOR II | $202,619 | $0 | $0 | $0 | $185,471 | $0 | $23,641 | $0 | $11,613 | $0 | $423,344 | $0 | $0 | $0 |
| GRANT N COLFAX | ||||||||||||||
| GLOBAL PROGRAM LEADER I | $218,830 | $0 | $50,000 | $0 | $15,225 | $0 | $18,017 | $0 | $11,556 | $0 | $313,628 | $0 | $0 | $0 |
| TRAD M HATTON | ||||||||||||||
| CHIEF OF PARTY | $121,085 | $0 | $0 | $0 | $151,651 | $0 | $14,530 | $0 | $11,441 | $0 | $298,707 | $0 | $0 | $0 |
| RAMONDA ANNE BYRKIT | ||||||||||||||
| COUNTRY PROGRAM LEADER I | $173,374 | $0 | $0 | $0 | $81,556 | $0 | $20,805 | $0 | $11,551 | $0 | $287,286 | $0 | $0 | $0 |
| DUNCAN OWENS EARLE | ||||||||||||||
| ASSOCIATE DIRECTOR II | $217,223 | $0 | $0 | $0 | $32,625 | $0 | $26,067 | $0 | $6,160 | $0 | $282,075 | $0 | $0 | $0 |
Supplemental Information Detail SupplementalInformationDetail (2 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| PART I, LINE 1A | HOUSING ALLOWANCE & TAX INDEMNIFICATION ARE ONLY PROVIDED TO THOSE INDIVIDUALS WHO ARE EXPATRIATE EMPLOYEES. ALL BENEFIT PAYMENTS ARE MADE ACCORDING TO OUR EXPATRIATE POLICY. PART I, LINE 3: PATH ENGAGES WITH A CONSULTING FIRM TO REVIEW THE COMPENSATION FOR EACH OF THE SENIOR MANAGEMENT POSITION. PATH PROVIDES AN ANNUAL SALARY ADJUSTMENT EACH JANUARY BASED ON THE OVERALL LABOR MARKET MOVEMENT. |
| PART I, LINE 7 | BONUS COMPENSATION HAS BEEN REFLECTED IN PART II, COLUMN (B)(II). |
Schedule M IRS990ScheduleM
Securities Publicly Traded SecuritiesPubliclyTradedGrp
| Field | Value | IRS element (for citing) |
|---|---|---|
| Non Cash Checkbox | Yes (X) | NonCashCheckboxInd |
| Contribution | 25 | ContributionCnt |
| Noncash Contributions Rpt F990 | $182,112 | NoncashContributionsRptF990Amt |
| Method Of Determining Revenues | FMV | MethodOfDeterminingRevenuesTxt |
Other Non Cash Contri Table OtherNonCashContriTableGrp (4 entries)
| Non Cash CheckboxNonCashCheckboxInd | DescDesc | ContributionContributionCnt | Noncash Contributions Rpt F990NoncashContributionsRptF990Amt | Method Of Determining RevenuesMethodOfDeterminingRevenuesTxt |
|---|---|---|---|---|
| Yes (X) | SUPPLIES | 2 | $354,007 | COST OR SALES PRICE |
| Yes (X) | SOFTWARE | 1 | $153,600 | COST OR SALES PRICE |
| Yes (X) | AUCTION ITEMS | 31 | $29,250 | COST OR SALES PRICE |
| Yes (X) | RAFFLE ITEMS | 24 | $3,131 | COST OR SALES PRICE |
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form8283 Received | 0 | Form8283ReceivedCnt |
| Any Property That Must Be Held | 0 | AnyPropertyThatMustBeHeldInd |
| Review Process Unusual NC Gifts | Yes (1) | ReviewProcessUnusualNCGiftsInd |
| Third Parties Used | 0 | ThirdPartiesUsedInd |
Supplemental Information Detail SupplementalInformationDetail
| Field | Value | IRS element (for citing) |
|---|---|---|
| Form And Line Reference | PART I, COLUMN (B): | FormAndLineReferenceDesc |
| Explanation | THIS COLUMN REFLECTS THE NUMBER OF CONTRIBUTIONS. SCHEDULE M, PART I, LINES 27 AND 28: THESE LINES CONTAIN ITEMS DONATED FOR THE AUCTION AND RAFFLE EVENT. THIS EVENT IS FURTHER DISCUSSED IN SCHEDULE G, PART II. | ExplanationTxt |
Schedule O IRS990ScheduleO
Supplemental Information Detail SupplementalInformationDetail (7 entries)
| Form And Line ReferenceFormAndLineReferenceDesc | ExplanationExplanationTxt |
|---|---|
| FORM 990, PART I, LINE 1 | PATH IS THE LEADER IN GLOBAL HEALTH INNOVATION. AN INTERNATIONAL NONPROFIT ORGANIZATION, WE SAVE LIVES AND IMPROVE HEALTH, ESPECIALLY AMONG WOMEN AND CHILDREN. WE ACCELERATE INNOVATION ACROSS FIVE PLATFORMS-VACCINES, DRUGS, DIAGNOSTICS, DEVICES, AND SYSTEM AND SERVICE INNOVATIONS-THAT HARNESS OUR ENTREPRENEURIAL INSIGHT, SCIENTIFIC AND PUBLIC HEALTH EXPERTISE, AND PASSION FOR HEALTH EQUITY. BY MOBILIZING PARTNERS AROUND THE WORLD, WE TAKE INNOVATION TO SCALE, WORKING ALONGSIDE COUNTRIES PRIMARILY IN AFRICA AND ASIA TO TACKLE THEIR GREATEST HEALTH NEEDS. TOGETHER, WE DELIVER MEASURABLE RESULTS THAT DISRUPT THE CYCLE OF POOR HEALTH. OUR ROBUST MONITORING AND EVALUATION IS INTEGRAL TO THESE EFFORTS. AT EVERY STAGE, WE ASSESS AND ALIGN OUR PROGRESS AGAINST PROJECT, FUNDER, AND ORGANIZATIONAL TARGETS, AND EVALUATE OPPORTUNITIES TO INCREASE OUR EFFICINECY AND IMPACT. IN 2014, PATH AND OUR PARTNERS AND SUPPORTERS REACHED MORE THAN 160 MILLION PEOPLE WITH LIFESAVING HEALTH SOLUTIONS. OUR FUNDERS AND COLLABORATORS FROM ACROSS THE PUBLIC, PRIVATE, AND CORPORATE SECTORS ARE PIVOTAL TO OUR SUCCESS. THEIR CONTRIBUTIONS SUPPORT OUR WIDE-REACHING WORK TO ACCELERATE INNOVATION TO SAVE LIVES AND IMPROVE HEALTH WORLDWIDE. |
| FORM 990, PART III, LINE 4A | IN A KEY 2014 MILESTONE, WE LAUNCHED AN AFFORDABLE, EASY-TO-USE DIAGNOSTIC TEST THAT CAN QUICKLY DETECT PREVIOUS EXPOSURE TO THE PARASITE THAT CAUSES RIVER BLINDNESS (ONCHOCERCIASIS). THE TEST IS FAST, ACCURATE, AND TAILORED FOR USE IN THE POOR RURAL COMMUNITIES WHERE THE DISEASE IS MOST COMMON. PATH HAS WORKED WITH PARTNERS SINCE 2010 TO DEVELOP THE TEST AND BRING IT TO MARKET. WE TESTED AND REFINED THE DIAGNOSTIC, CONDUCTED LABORATORY AND FIELD EVALUATIONS, IDENTIFIED THE MANUFACTURER, AND HELPED ENSURE THE PRODUCT MET QUALITY AND PERFORMANCE REQUIREMENTS. THE TEST REPRESENTS THE FIRST IN A SUITE OF DIAGNOSTICS AIMED AT ELIMINATING NEGLECTED TROPICAL DISEASES, A GROUP OF ILLNESSES THAT AFFECT MORE THAN 1 BILLION PEOPLE WORLDWIDE. IN 2014, THE FIRST 15,000 TESTS WERE SHIPPED TO NIGERIA AND TOGO FOR USE IN DEMONSTRATION STUDIES, LAYING THE GROUNDWORK FOR FURTHER EXPANSION IN 2015. WE ARE ALSO EXPANDING OUR WORK TO BRING TO MARKET A NEW DUAL-DETECTION TEST FOR BOTH RIVER BLINDNESS AND LYMPHATIC FILARIASIS, A DISEASE THAT CAUSES DISFIGUREMENT AND DISABILITY AND OFTEN AFFECTS THE SAME COMMUNITIES AS RIVER BLINDNESS. AND WE ARE LEVERAGING OUR EXPERTISE AND GLOBAL NETWORK OF PARTNERS TO SPEED DEVELOPMENT OF ADDITIONAL DIAGNOSTIC TOOLS FOR NEGLECTED TROPICAL DISEASES. FINALLY, WE ARE PIONEERING THE USE OF DIAGNOSTICS FOR MALARIA ELIMINATION. WE ARE IMPROVING ACCESS TO AVAILABLE TESTS WHILE DEVELOPING NEW OPTIONS THAT PROVIDE ACCESS TO PROPER TREATMENT AND THAT CAN DETECT LOW LEVELS OF MALARIA INFECTION THAT MIGHT OTHERWISE BE MISSED. IN 2014, WE INCREASED THE USE OF HIGH-QUALITY MALARIA DIAGNOSIS AND TREATMENT IN 15 COUNTRIES IN AFRICA AND THE MEKONG REGION. OUR DIGITAL HEALTH SOLUTIONS GROUP CONTINUED TO WORK WITH GLOBAL HEALTH STAKEHOLDERS TO IDENTIFY, ADAPT, AND IMPLEMENT INFORMATION AND COMMUNICATIONS TECHNOLOGIES PRODUCTS, POLICIES, AND PROCESSES TO ENCOURAGE BETTER DATA USE AND DECISION-MAKING AND IMPROVE HEALTH. ACCOMPLISHMENTS IN 2014 INCLUDED SERVING AS A LEAD PARTNER IN THE BETTER IMMUNIZATION DATA INITIATIVE AND WORKING WITH TANZANIA'S MINISTRY OF HEALTH; GAVI, THE VACCINE ALLIANCE; AND OTHER PARTNERS TO INTRODUCE AN INEXPENSIVE, EASY-TO-USE, AND RELIABLE BARCODE TECHNOLOGY INTO THE NATIONAL LOGISTICS MANAGEMENT SYSTEM FOR VACCINES AND OTHER SUPPLIES. WE ALSO WORKED CLOSELY WITH VACCINE MANUFACTURERS TO UPDATE THE BARCODES USED ON VACCINE PACKAGING. OUR VISION IS THAT IN FIVE YEARS EVERY COUNTRY WILL BE ABLE TO TRACK PRODUCTS FROM MANUFACTURER TO RECIPIENT, IDENTIFY AND PREDICT STOCKOUTS, AND ENSURE THAT THE RIGHT GOODS ARE IN PLACE TO DELIVER LIFESAVING HEALTH IMPACT. |
| FORM 990, PART III, LINE 4B | THE FIVE-YEAR WINDOW OF OPPORTUNITY PROJECT (2011-2016) CONTINUED TO IMPROVE MATERNAL, NEWBORN, AND CHILD HEALTH (MNCH) AND DEVELOPMENT IN FIVE DISTRICTS IN SOUTH AFRICA AND MOZAMBIQUE. AMONG OTHER 2014 HIGHLIGHTS, WE CONTINUED WORK TO DEVELOP NATIONAL MNCH NUTRITION STRATEGIES AND SUPPORTED PROGRESS TOWARD A NEW NATIONAL EARLY CHILDHOOD DEVELOPMENT POLICY. AT THE DISTRICT LEVEL, WE STRENGTHENED COLLABORATIONS BETWEEN STAKEHOLDERS; IMPROVED DATA MANAGEMENT AND USE; ENGAGED COMMUNITIES TO IMPROVE HEALTH; AND PROVIDED SUPPORT AND TECHNICAL ASSISTANCE TO MORE THAN 40 COMMUNITY-BASED ORGANIZATIONS. SO FAR, THE PROJECT HAS TRAINED THOUSANDS OF HEALTH AND DEVELOPMENT PROFESSIONALS IN MNCH AND PROVIDED EDUCATION AND ASSISTANCE TO TENS OF THOUSANDS OF HOUSEHOLDS. TO DATE, OUR EFFORTS HAVE INCREASED WOMEN RECEIVING EARLY ANTENATAL CARE OVER STARTING NUMBERS IN PARTICIPATING AREAS, AND MORE CHILDREN ARE EXCLUSIVELY BREASTFED AT 14 WEEKS OF AGE, DECREASING THE BURDEN OF LIFE-THREATENING DIARRHEA. WE ALSO CONTINUED OUR BOLD PORTFOLIO OF EARLY CHILDHOOD DEVELOPMENT EFFORTS, WHICH HELP TO ENSURE THAT MORE CHILDREN RECEIVE THE STIMULATION (FROM CONVERSATION TO SIMPLE TOYS) THAT HELPS THEIR MINDS DEVELOP TO THEIR FULL POTENTIAL. IN 2014, WE BUILT ON MOMENTUM AND LESSONS LEARNED FROM PRIOR EFFORTS TO EXPAND OUR WORK IN KENYA AND MOZAMBIQUE. THE MAXIMISING THE QUALITY OF SCALING UP NUTRITION PROJECT SUPPORTED MORE THAN 20 PROJECTS TO ADDRESS UNDERNUTRITION IN 17 FOCUS COUNTRIES. THE PATH-LED CONSORTIUM IS IMPROVING HEALTH AND NUTRITION BY STRENGTHENING GOVERNMENT AND NATIONAL POLICIES; SCALING UP PROVEN INTERVENTIONS, SUCH AS FOOD SUPPLEMENTATION AND FORTIFICATION; AND INTEGRATING SYSTEMIC CHANGES, SUCH AS AGRICULTURAL AND WATER AND SANITATION IMPROVEMENTS, INTO EXISTING PROGRAMS. OUR PROJECTING HEALTH PROJECT ALSO MADE STRIDES. GETTING PEOPLE TO CHANGE THEIR HABITS IN FAVOR OF HEALTHIER BEHAVIORS IS ONE OF THE BIGGEST CHALLENGES IN GLOBAL HEALTH. PROJECTING HEALTH EMPOWERS LOCAL COMMUNITY MEMBERS TO PRODUCE, EDIT, AND STAR IN HEALTH EDUCATION VIDEOS CUSTOMIZED FOR LOCAL CONTEXTS AND DIALECTS. WITH A LOW-COST, PORTABLE PROJECTOR AND A WHITE SHEET FOR A SCREEN, THE VIDEOS ARE REACHING REMOTE COMMUNITIES IN ETHIOPIA AND INDIA WITH ACCURATE INFORMATION ON BREASTFEEDING, IMMUNIZATION, CHILDBIRTH, AND MORE. |
| FORM 990, PART VI, SECTION B, LINE 11 | THE FORM 990 WAS PREPARED BY AN OUTSIDE ACCOUNTING FIRM USING INFORMATION PROVIDED BY PATH ACCOUNTING SERVICES STAFF. PATH SENIOR MANAGEMENT REVIEWED THE DRAFT FORM. A COPY OF THE 990 WAS SENT TO THE BOARD OF DIRECTORS FOR COMMENT. AFTER THE COMMENT PERIOD, THE PRESIDENT/CEO SIGNED THE RETURN. |
| FORM 990, PART VI, SECTION B, LINE 12C | BOARD MEMBERS, PATH MANAGEMENT, AND ALL STAFF ABOVE A DESIGNATED LEVEL IN THE ORGANIZATION MUST COMPLETE A CONFLICT OF INTEREST DISCLOSURE FORM EACH YEAR. ALL FORMS ARE REVIEWED AND KEPT ON FILE. A CONFLICT MANAGEMENT PLAN IS DEVELOPED FOR ANY EMPLOYEE WITH A SIGNIFICANT ACTUAL OR PERCEIVED CONFLICT OF INTEREST. |
| FORM 990, PART VI, SECTION B, LINE 15 | THE BOARD'S EXECUTIVE COMPENSATION COMMITTEE ANNUALLY REVIEWS SALARY AND BENEFITS FOR EXECUTIVE EMPLOYEE POSITIONS AND PROVIDES GUIDANCE TO THE CEO ON COMPENSATION DECISIONS FOR EXECUTIVE POSITIONS. THE COMPENSATION AND BENEFITS FOR PATH'S PRESIDENT AND CEO ARE REVIEWED AND APPROVED BY THE ENTIRE BOARD OF DIRECTORS EACH YEAR AT THE DECEMBER BOARD MEETING. PATH ROUTINELY USES THE SERVICES OF EXTERNAL FIRMS TO ASSESS AND BENCHMARK EXECUTIVE COMPENSATION (PRESIDENT/CEO, VICE PRESIDENTS, AND EXECUTIVE TEAM MEMBERS). THE LAST MAJOR REVIEW WAS COMPLETED IN 2014, WHEN PATH ENGAGED MERCER (A COMPENSATION, BENEFITS, AND HUMAN RESOURCES CONSULTING FIRM) TO REVIEW CURRENT AND PROPOSED BASE SALARIES OF PATH'S PRESIDENT/CEO, VICE PRESIDENTS, AND EXECUTIVE TEAM MEMBERS. MERCER USED DATA FROM MULTIPLE SOURCES TO EVALUATE CURRENT AND PROPOSED BASE SALARIES FOR THESE POSITIONS. THE BOARD'S EXECUTIVE COMPENSATION COMMITTEE REVIEWED THE MERCER REPORT AND APPROVED THE COMPENSATION PACKAGES FOR THE VICE PRESIDENTS AND EXECUTIVE TEAM. ADDITIONALLY, MERCER REVIEWED THE PROPOSED TOTAL COMPENSATION AND BENEFIT PACKAGE FOR THE PRESIDENT/CEO POSITION AND OBTAINED A SIGNIFICANT NUMBER OF DATA POINTS TO ASCERTAIN ITS REASONABLENESS AND APPROPRIATENESS. THE BOARD APPROVED THE COMMITTEE'S RECOMMENDATION FOR THE PRESIDENT/CEO'S TOTAL COMPENSATION PACKAGE. |
| FORM 990, PART VI, SECTION C, LINE 19 | PATH MAKES ITS GOVERNING DOCUMENTS, CONFLICT OF INTEREST POLICY, AND FINANCIAL STATEMENTS AVAILABLE TO THE PUBLIC UPON REQUEST; MOST DOCUMENTS ARE ALSO AVAILABLE ONLINE. |
Schedule R IRS990ScheduleR
Id Related Tax Exempt Org IdRelatedTaxExemptOrgGrp (3 entries)
| Address Line1USAddress/AddressLine1Txt | CityUSAddress/CityNm | State AbbreviationUSAddress/StateAbbreviationCd | ZIPUSAddress/ZIPCd | EINEIN | Primary ActivitiesPrimaryActivitiesTxt | Legal Domicile StateLegalDomicileStateCd | Exempt Code SectionExemptCodeSectionTxt | Public Charity StatusPublicCharityStatusTxt | Business Name Line1DirectControllingEntityName/BusinessNameLine1Txt | Controlled OrganizationControlledOrganizationInd | Address Line1ForeignAddress/AddressLine1Txt | CityForeignAddress/CityNm | CountryForeignAddress/CountryCd | Legal Domicile Foreign CountryLegalDomicileForeignCountryCd |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| PATH VACCINE SOLUTIONS | ||||||||||||||
| 2201 WESTLAKE AVENUE | SEATTLE | WA | 98109 | 830431851 | ADVANCE DEVELOPMENT OF VACCINES TO IMPROVE THE HEALTH OF CHILDREN | WA | 501(C)(3) | LINE 11A | PATH | Yes (1) | ||||
| PATH DRUG SOLUTIONS | ||||||||||||||
| 280 UTAH AVENUE SUITE 250 | SAN FRANCISCO | CA | 94080 | 943384500 | DEVELOPMENT & DISTRIBUTION OF SAFE, EFFECTIVE, AND AFFORDABLE MEDICINES | CA | 501(C)(3) | LINE 11A | PATH | Yes (1) | ||||
| FOUNDATION FOR APPROPRIATE TECHNOLOGIES IN HEALTH - SWITZERLAND | ||||||||||||||
| EDUCATIONAL AND SCIENTIFIC PROMOTION OF HEALTH | N/A | N/A | PATH | Yes (1) | 207 ROUTE DE FERNEY 1218 LE GRAND-S | GENEVA | SZ | SZ | ||||||
| Field | Value | IRS element (for citing) |
|---|---|---|
| Receipt Of Int Annts Rnts Rylts | 0 | ReceiptOfIntAnntsRntsRyltsInd |
| Gift Grnt Or Cap Contri To Oth Org | Yes (1) | GiftGrntOrCapContriToOthOrgInd |
| Gift Grnt Cap Contri From Oth Org | Yes (1) | GiftGrntCapContriFromOthOrgInd |
| Loans Or Guarantees To Other Org | 0 | LoansOrGuaranteesToOtherOrgInd |
| Loans Or Guarantees From Oth Org | 0 | LoansOrGuaranteesFromOthOrgInd |
| Div Related Organization | 0 | DivRelatedOrganizationInd |
| Asset Sale To Other Org | 0 | AssetSaleToOtherOrgInd |
| Asset Purchase From Other Org | 0 | AssetPurchaseFromOtherOrgInd |
| Asset Exchange | 0 | AssetExchangeInd |
| Rental Of Facilities To Oth Org | 0 | RentalOfFacilitiesToOthOrgInd |
| Rental Of Fclts From Oth Org | 0 | RentalOfFcltsFromOthOrgInd |
| Perform Of Services For Oth Org | 0 | PerformOfServicesForOthOrgInd |
| Perform Of Services By Other Org | 0 | PerformOfServicesByOtherOrgInd |
| Sharing Of Facilities | 0 | SharingOfFacilitiesInd |
| Paid Employees Sharing | 0 | PaidEmployeesSharingInd |
| Reimbursement Paid To Other Org | 0 | ReimbursementPaidToOtherOrgInd |
| Reimbursement Paid By Other Org | 0 | ReimbursementPaidByOtherOrgInd |
| Transfer To Other Org | 0 | TransferToOtherOrgInd |
| Transfer From Other Org | 0 | TransferFromOtherOrgInd |
Transactions Related Org TransactionsRelatedOrgGrp (5 entries)
| Transaction TypeTransactionTypeTxt | InvolvedInvolvedAmt | Method Of Amount DeterminationMethodOfAmountDeterminationTxt |
|---|---|---|
| PATH VACCINE SOLUTIONS | ||
| C | $15,586,258 | FMV |
| PATH DRUG SOLUTIONS | ||
| C | $5,119,574 | FMV |
| PATH DRUG SOLUTIONS | ||
| B | $798,172 | FMV |
| FOUNDATION FOR APPROPRIATE TECHNOLOGIES IN HEALTH - SWITZERLAND | ||
| C | $2,151,116 | FMV |
| FOUNDATION FOR APPROPRIATE TECHNOLOGIES IN HEALTH - SWITZERLAND | ||
| B | $5,656,857 | FMV |